PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21621119-3 2011 We evaluated whether ERCC1 expression could predict the treatment response and survival outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy. Cisplatin 174-183 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 21-26 21902499-0 2011 Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Cisplatin 28-37 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-102 21902499-8 2011 CONCLUSION: Genetic polymorphisms in ERCC1 may be valuable predictors of cisplatin-induced nephrotoxicity. Cisplatin 73-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 21855036-5 2011 ERCC1 has recently been shown to be closely associated with outcome in patients with non-small-cell lung cancer (NSCLC): both high ERCC1 protein and gene expression are associated with resistance to cisplatin-based chemotherapy and better outcome without treatment. Cisplatin 199-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21855036-5 2011 ERCC1 has recently been shown to be closely associated with outcome in patients with non-small-cell lung cancer (NSCLC): both high ERCC1 protein and gene expression are associated with resistance to cisplatin-based chemotherapy and better outcome without treatment. Cisplatin 199-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 131-136 21298384-6 2011 In patients treated with cisplatin-based regimens, median PFS and OS were significantly longer in ERCC1-negative group than in ERCC1-positive group, respectively (4.6 vs. 1.9 months, p = 0.014; 9.1 vs. 7.9 months, p = 0.017). Cisplatin 25-34 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 98-103 21298384-6 2011 In patients treated with cisplatin-based regimens, median PFS and OS were significantly longer in ERCC1-negative group than in ERCC1-positive group, respectively (4.6 vs. 1.9 months, p = 0.014; 9.1 vs. 7.9 months, p = 0.017). Cisplatin 25-34 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 127-132 21298384-10 2011 CONCLUSIONS: ERCC1 shows a significant prognostic value in ABTA patients treated with cisplatin. Cisplatin 86-95 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 21298384-11 2011 A survival benefit was observed in ERCC1-negative patients from cisplatin-containing chemotherapy but not from oxaliplatin-containing ones. Cisplatin 64-73 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 21298384-12 2011 The action mechanism of ERCC1 on cisplatin may be different from that on oxaliplatin. Cisplatin 33-42 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 21750204-2 2011 We and others have previously shown the influence of ERCC1 expression upon survival rates and benefit of cisplatin-based chemotherapy in patients with resected non-small-cell lung cancer (NSCLC). Cisplatin 105-114 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 53-58 22977580-1 2011 Excision repair cross-complementation group 1 (ERCC1) protein has been associated with cisplatin resistance. Cisplatin 87-96 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 21621119-12 2011 CONCLUSION: These results suggest that ERCC1 expression might be a useful predictive marker in patients with locally advanced nasopharyngeal cancer who are under consideration for cisplatin-based concurrent chemoradiotherapy. Cisplatin 180-189 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-44 21177407-4 2011 Several reports indicate that the excision repair cross-complementing group 1 (ERCC1) gene is associated with resistance to cisplatin and radiation therapy. Cisplatin 124-133 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 34-77 21327329-2 2011 Among the DNA repair-related proteins, excision repair cross-complementation group 1 (ERCC1) has been shown to be essential for repairing cisplatin-induced interstrand cross-linkage. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-84 21327329-2 2011 Among the DNA repair-related proteins, excision repair cross-complementation group 1 (ERCC1) has been shown to be essential for repairing cisplatin-induced interstrand cross-linkage. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-91 21357694-6 2011 Down-regulating ERCC1-XPF in BER-deficient cells restored cisplatin sensitivity. Cisplatin 58-67 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 16-21 21177407-4 2011 Several reports indicate that the excision repair cross-complementing group 1 (ERCC1) gene is associated with resistance to cisplatin and radiation therapy. Cisplatin 124-133 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 79-84 21177407-7 2011 We then examined by immunohistochemistry that whether ERCC1 nuclear staining correlates with the efficacy of CRT using cisplatin in 22 patients with MIBC. Cisplatin 119-128 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 54-59 21076943-0 2011 Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 21076943-2 2011 This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Cisplatin 104-113 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 63-68 21076943-2 2011 This study was designed to investigate the correlation between ERCC1 expression and chemosensitivity to cisplatin (CDDP) in patients with hepatocellular carcinoma (HCC). Cisplatin 115-119 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 63-68 21076943-5 2011 ERCC1 siRNA was transfected to PLC/RPF/5 to investigate the correlation of ERCC1 expression and CDDP sensitivity. Cisplatin 96-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21076943-11 2011 ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). Cisplatin 86-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21076943-11 2011 ERCC1 expression was inhibited by ERCC1 siRNA transfection and the LC50 value (nM) of CDDP was reduced from 25.7 to 12.5 (p = 0.01). Cisplatin 86-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 34-39 21076943-12 2011 CONCLUSIONS: Increased ERCC1 expression is associated with CDDP resistance in HCC specimens and cell lines. Cisplatin 59-63 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 23-28 20605357-8 2011 Resistance to cisplatin-containing chemotherapy in high-ERCC1 score tumor was not observed in Group II. Cisplatin 14-23 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 56-61 21364592-0 2011 CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Cisplatin 67-76 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 11-16 21286668-0 2011 Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Cisplatin 68-77 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 25-30 21286668-1 2011 The aim of this study was to investigate the relationship between the ERCC1-C8092A, ERCC1-C19007T and GSTP1-A105G genetic polymorphisms and the curative effect of cisplatin-based chemotherapy in advanced esophageal carcinoma. Cisplatin 163-172 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 70-75 21286668-1 2011 The aim of this study was to investigate the relationship between the ERCC1-C8092A, ERCC1-C19007T and GSTP1-A105G genetic polymorphisms and the curative effect of cisplatin-based chemotherapy in advanced esophageal carcinoma. Cisplatin 163-172 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 84-89 21286668-7 2011 In conclusion, the ERCC1-C8092A genetic polymorphism may be correlated with the efficacy of cisplatin-based chemotherapy in cases of advanced esophageal carcinoma. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 21521014-0 2011 SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 8-13 21364592-1 2011 BACKGROUND: We evaluated the association between polymorphisms of cytochrome P450 2A6 (CYP2A6)/excision repair cross-complementation group 1 (ERCC1)/X-ray repair cross-complementing group 1(XRCC1) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin. Cisplatin 281-290 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 142-147 21364592-6 2011 CONCLUSION: Polymorphisms of CYP2A6 and ERCC1 19442C>A correlated with the efficacy of S-1/cisplatin. Cisplatin 94-103 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 40-45 21426588-0 2011 High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. Cisplatin 31-40 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 5-10 21426588-1 2011 BACKGROUND: This study was to evaluate the effect of excision repair cross-complementation group 1(ERCC1) expression on response to cisplatin-based induction chemotherapy (IC) followed by concurrent chemoradiation (CCRT) in locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) patients. Cisplatin 132-141 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 99-104 21426588-10 2011 CONCLUSIONS: Our study suggest that a high expression of ERCC1 predict a poor response and survival to cisplatin-based IC followed by CCRT in patients with locally advanced unresectable HNSCC in betel nut chewing area. Cisplatin 103-112 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 57-62 20801905-0 2011 ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21315089-6 2011 Both ERCC1 mRNA and protein expression levels increased upon cisplatin treatment, peaking at 4h post-treatment, however there were no differences between the two alleles (p>0.05). Cisplatin 61-70 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 5-10 20801905-1 2011 BACKGROUND: We recently demonstrated that excision repair cross-complementing group 1 protein (ERCC1) is predictive of adjuvant cisplatin-based chemotherapy benefit in resected non-small-cell lung cancer (NSCLC). Cisplatin 128-137 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 20801905-3 2011 We hypothesised that there might be an increased incidence of BMs in ERCC1-negative non-SCCs when treated with adjuvant cisplatin-based chemotherapy. Cisplatin 120-129 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 69-74 21586890-8 2011 As for the predictive marker of cisplatin, ERCC1 may predict survival in bladder cancer treated by platinum-based therapy. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 43-48 21165580-0 2011 Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 80-85 20846399-0 2010 Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 106-111 21093896-9 2011 CONCLUSIONS: The ERCC1 expression patterns in pretreatment specimens may thus facilitate the prediction of responses to cisplatin-based NAC. Cisplatin 120-129 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 17-22 21093896-10 2011 We propose that patients expressing low levels of ERCC1 derive the most benefit from cisplatin-based NAC. Cisplatin 85-94 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-55 20627363-2 2011 In this study, we assessed whether the presence of polymorphisms in ERCC1, XPD, RRM1 and MDR1 genes can affect the efficacy and the tolerability of cisplatin and vinorelbine in NSCLC patients. Cisplatin 148-157 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 68-73 21206986-0 2011 ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation. Cisplatin 162-171 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21206986-10 2011 Collectively, our results suggest that high ERCC1 expression seems to be associated with better OS rates in HNSCC patients submitted to adjuvant cisplatin-based chemoradiation. Cisplatin 145-154 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-49 21091775-0 2010 Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-45 21091775-0 2010 Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 21091775-14 2010 These results suggest a negative contribution by ERCC1expression to PFS in metastatic urothelial carcinoma patients treated with cisplatin-based chemotherapy. Cisplatin 129-138 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 49-54 21229648-2 2010 Existence of excisional repair cross complementation1 (ERCC1) is implicated in resistance to cisplatin treatment. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-53 21229648-2 2010 Existence of excisional repair cross complementation1 (ERCC1) is implicated in resistance to cisplatin treatment. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 55-60 20846399-10 2010 Over-expression increased ICL repair and rendered TTC more resistant to cisplatin, which suggests that ERCC1-XPF is rate-limiting for repair of ICLs resulting in the observed cisplatin hypersensitivity of TTC. Cisplatin 72-81 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 103-108 20846399-10 2010 Over-expression increased ICL repair and rendered TTC more resistant to cisplatin, which suggests that ERCC1-XPF is rate-limiting for repair of ICLs resulting in the observed cisplatin hypersensitivity of TTC. Cisplatin 175-184 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 103-108 19962780-9 2010 In contrast, blocking ERK1/2 activation by U0126 (an MKK1/2 inhibitor) decreased cisplatin-elicited ERCC1 expression and enhanced cisplatin-induced cytotoxicity. Cisplatin 81-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 100-105 20823140-9 2010 Knockdown of Snail in the high endogenous Snail/ERCC1 cell line OECM-1 downregulated ERCC1 expression and attenuated cisplatin resistance. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 48-53 20823140-10 2010 Furthermore, suppression of ERCC1 in Snail- or NBS1-overexpressing HNSCC cells enhanced sensitivity to cisplatin. Cisplatin 103-112 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 28-33 20823140-12 2010 In patients with HNSCC, coexpression of Snail and ERCC1 correlated with cisplatin resistance and a poor prognosis. Cisplatin 72-81 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-55 20823140-13 2010 CONCLUSIONS: Activation of ERCC1 by Snail is critical in the generation of cisplatin resistance of HNSCC cells. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 21029626-0 2010 [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer]. Cisplatin 77-86 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-72 21029626-1 2010 OBJECTIVE: To investigate the correlation between excision repair cross-complementing 1 (ERCC1) expression and cisplatin sensitivity in non-small cell lung cancer (NSCLC). Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-87 21029626-1 2010 OBJECTIVE: To investigate the correlation between excision repair cross-complementing 1 (ERCC1) expression and cisplatin sensitivity in non-small cell lung cancer (NSCLC). Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 89-94 21029626-14 2010 CONCLUSION: An elevated expression of ERCC1 is an important factor for cisplatin insensitivity in NSCLC. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-43 20332140-10 2010 CONCLUSIONS: Clinically applicable evaluation of ERCC1 status predicted cisplatin sensitivity in the largest randomized patient population with advanced NSCLC reported to date. Cisplatin 72-81 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 49-54 19962780-0 2010 Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Cisplatin 16-25 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 70-75 19962780-10 2010 Depletion of endogenous ERCC1 expression by si-ERCC1 RNA transfection significantly enhanced cisplatin"s cytotoxic effect. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 19962780-5 2010 Exposure of human NSCLC cells to emodin decreased cisplatin-elicited ERK1/2 activation and ERCC1 protein induction by increasing instability of ERCC1 protein. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 144-149 19962780-7 2010 However, emodin alone or combined with cisplatin significantly decreased expression of ERCC1 mRNA levels. Cisplatin 39-48 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 87-92 19962780-10 2010 Depletion of endogenous ERCC1 expression by si-ERCC1 RNA transfection significantly enhanced cisplatin"s cytotoxic effect. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 19962780-12 2010 Further investigation of combined emodin and cisplatin may lead to novel therapy in the future for NSCLC through down-regulating expression of ERCC1. Cisplatin 45-54 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 143-148 20622964-0 2010 Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 20689757-2 2010 We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair cross-complementing 1 (ERCC1) may help identify the group of patients benefiting from cisplatin-based adjuvant chemotherapy. Cisplatin 231-240 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 129-166 20689757-2 2010 We hypothesized that assessing the gene expression of the chemotherapy response modifiers multidrug resistance gene 1 (MDR1) and excision repair cross-complementing 1 (ERCC1) may help identify the group of patients benefiting from cisplatin-based adjuvant chemotherapy. Cisplatin 231-240 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 168-173 20689757-8 2010 CONCLUSIONS: High MDR1 and ERCC1 gene expressions are associated with inferior outcome after cisplatin-based adjuvant chemotherapy for locally advanced bladder cancer. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 20622964-1 2010 PURPOSE: The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy. Cisplatin 196-205 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 60-65 20403548-1 2010 ERCC1 plays a critical role in the repair of lesions in DNA induced by cisplatin. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 20372803-2 2010 Testicular germ cell tumours (TGCT) show exquisite sensitivity towards cisplatin, and this has been connected to low levels of the NER proteins ERCC1 and XPF. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 144-149 19626585-0 2010 Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Cisplatin 62-71 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 8-13 19626585-1 2010 Overexpression of ERCC1 mRNA is associated with drug resistance to cisplatin in human gliomas, but the role of the ERCC1 promoter in drug resistance has not been demonstrated. Cisplatin 67-76 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 19626585-2 2010 We have used sodium bisulfite sequencing to compare ERCC1 promoter methylation patterns in cisplatin-sensitive and cisplatin-resistant glioma cells. Cisplatin 91-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 52-57 19626585-5 2010 Hypermethylation was observed in the upstream 5Kb region of the ERCC1 promoter of cisplatin-sensitive glioma cell lines. Cisplatin 82-91 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 64-69 19626585-6 2010 ERCC1 DNA methylation levels were highly variable in 32 human glioma samples ranging from 0.1 to 0.87, which have shown significant difference between cisplatin-sensitive samples and cisplatin-resistant samples (p < 0.05). Cisplatin 151-160 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 19626585-6 2010 ERCC1 DNA methylation levels were highly variable in 32 human glioma samples ranging from 0.1 to 0.87, which have shown significant difference between cisplatin-sensitive samples and cisplatin-resistant samples (p < 0.05). Cisplatin 183-192 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 19626585-12 2010 ERCC1 DNA methylation could regulate the expression of downstream mRNA and protein, and was associated with cisplatin chemosensitivity. Cisplatin 108-117 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 20085902-0 2010 Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Cisplatin 113-122 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-49 20403548-5 2010 At present ERCC1 appears to be a promising biomarker for predicting the benefit of cisplatin based chemotherapy and its modulation could allow sensitisation of tumour cells to this drug. Cisplatin 83-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 11-16 20443070-3 2010 Low excision repair cross-complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) levels have been associated with increased sensitivity to cisplatin and gemcitabine, respectively, while reduced class III beta-tubulin expression has been associated with taxane activity. Cisplatin 155-164 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 4-49 20677561-0 2010 [Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy]. Cisplatin 120-129 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-43 20677561-2 2010 The aim of this study is to prospectively assess the association between single nucleotide polymorphisms of C8092A and codon118 in ERCC1 and drug response in 90 patients with advanced non-small cell lung cancer treated with cisplatin-based chemotherapy. Cisplatin 224-233 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 131-136 20189873-0 2010 Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Cisplatin 74-83 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 20443070-3 2010 Low excision repair cross-complementation group 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) levels have been associated with increased sensitivity to cisplatin and gemcitabine, respectively, while reduced class III beta-tubulin expression has been associated with taxane activity. Cisplatin 155-164 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 51-56 19832035-0 2009 The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. Cisplatin 60-69 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 15-20 19940136-9 2010 We discuss the impact of these findings for understanding how ERCC1 contributes to resistance of tumor cells to therapeutic agents such as cisplatin. Cisplatin 139-148 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 62-67 20044377-2 2010 SUMMARY: Cisplatin resistance has been associated with high rates of expression of endonucleases, a family of DNA repair proteins that includes ERCC1 and BRCA1. Cisplatin 9-18 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 144-149 20593954-0 2010 Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Cisplatin 78-87 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-62 19832035-3 2009 Further investigation showed that over-expressed exon VIII deficient ERCC1 variant failed to change the protein level of ERCC1 in cancer cells, but decreased the excision repair function of ERCC1 and enhanced sensitivity of cancer cells to cisplatin in a dose-dependent manner. Cisplatin 240-249 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 69-74 19832035-4 2009 The results indicate that ERCC1 exon VIII alternative splicing does exist in some ovarian cancer cell lines, and regulates cisplatin-resistance in ovarian cancer cells. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 26-31 19473860-3 2009 One possible mechanism for the acquired resistance to Cisplatin is an increase in DNA repair through the up-regulation of ERCC1, an essential component of the nucleotide excision repair complex. Cisplatin 54-63 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 122-127 19900859-9 2009 CONCLUSION: Our data suggested that determination of MRP1, LRP, and ERCC1 mRNA expression using RT-PCR in TBB samples might be helpful in predicting outcome of patients with advanced NSCLC treated with cisplatin-based chemotherapy and in optimizing therapeutic strategy based on the expression of these genes. Cisplatin 202-211 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 68-73 21475919-1 2009 Low excision repair cross-complementing 1 (ERCC1) has been associated with a favorable response to cisplatin (CDDP) in several types of malignancies. Cisplatin 99-108 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 4-41 21475919-1 2009 Low excision repair cross-complementing 1 (ERCC1) has been associated with a favorable response to cisplatin (CDDP) in several types of malignancies. Cisplatin 99-108 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 43-48 20082278-2 2009 The purpose of this study was to investigate the prognostic value of multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance-related protein (LRP), and excision repair cross-complementing 1 (ERCC1) in NSCLC patients receiving cisplatin-based adjuvant chemotherapy (cisplatin plus vinorelbine or gemcitabine) after tumor resection. Cisplatin 266-275 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 231-236 20082278-2 2009 The purpose of this study was to investigate the prognostic value of multidrug resistance protein 1 (MRP1), breast cancer resistance protein (BCRP), lung resistance-related protein (LRP), and excision repair cross-complementing 1 (ERCC1) in NSCLC patients receiving cisplatin-based adjuvant chemotherapy (cisplatin plus vinorelbine or gemcitabine) after tumor resection. Cisplatin 305-314 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 231-236 19473860-5 2009 As there are currently no effective inhibitors of this interaction, inhibition of the ERCC1/XPA interaction may provide an effective strategy for overcoming the development of Cisplatin-resistant cancers. Cisplatin 176-185 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-91 18804893-3 2009 Excision repair cross-complementation group 1 (ERCC1) has shown potential as a predictive marker in patients with NSCLC treated with cisplatin-based chemotherapy. Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-45 19620936-6 2009 Polymorphism-cisplatin interactions were highly significant in both OS (P = 0.002, P = 0.0001, and P < 0.0001) and PFS (P = 0.006, P = 0.008, and P = 0.0007) for XPD 312, XPD 751, and ERCC1 8092, respectively. Cisplatin 13-22 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 187-192 19620936-7 2009 In cisplatin-treated patients, variant alleles of XPD 312, XPD 751, and ERCC1 8092 were each associated with significantly improved OS (and PFS): adjusted hazard ratios of homozygous variants versus wild-type ranged from 0.22 [95% confidence interval (CI): 0.1-0.5] to 0.31 (95% CI: 0.1-0.7). Cisplatin 3-12 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 19123003-0 2009 Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation. Cisplatin 116-125 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 19123003-9 2009 CONCLUSIONS: This retrospective study indicates that immunostaining for ERCC1 may be useful for predicting survival in NSCLC patients receiving concurrent chemoradiotherapy with cisplatin and docetaxel, and can provide information critical for planning personalized chemotherapy. Cisplatin 178-187 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 19267403-2 2009 Although ERCC1 and other repair proteins have been investigated as markers of cisplatin resistance, reliable markers are still needed. Cisplatin 78-87 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-14 20719134-0 2009 [Effects of Expression of ERCC1, RRM1 on Survival Trend of Lung Cancer with Cisplatin Combine Gemcitabine Chemotherapy after Surgical Resection.]. Cisplatin 76-85 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 26-31 20719134-2 2009 The aim of this study was to explor the relationship of ERCC1, RRM1 expression and the benefits from postoperative cisplatin combined with gemcitabine (GP) chemotherapy in patients with non-small cell lung cancer (NSCLC). Cisplatin 115-124 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 56-61 20719134-12 2009 CONCLUSIONS: The NSCLC patients with high expression of ERCC1 and low expression of RRM1 get more probablely benefits from postoperative cisplatin combine gemcitabine chemotherapy. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 56-61 18804893-3 2009 Excision repair cross-complementation group 1 (ERCC1) has shown potential as a predictive marker in patients with NSCLC treated with cisplatin-based chemotherapy. Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 18823676-0 2009 Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 43-48 18623378-1 2008 BACKGROUND: Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). Cisplatin 114-123 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-57 20066897-7 2009 ERCC1 expression was significantly upregulated with cisplatin treatment. Cisplatin 52-61 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 19080461-1 2008 OBJECTIVE: To research the changes of cisplatin sensitivity by RNA interfering the excision repair cross-complementing (ERCC)1 gene in lung cancer cell lines. Cisplatin 38-47 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 120-126 19080461-6 2008 The sensitivity to cisplatin of A549 cell line was increased by 3.07 times after disturbing the ERCC1 gene. Cisplatin 19-28 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 96-101 19080461-7 2008 CONCLUSIONS: The sensitivity to cisplatin of lung cancer cell lines A549 could be enhanced by RNA interfering ERCC1 gene. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 110-115 18827563-4 2008 Moreover, RT-PCR analysis of molecular markers known to be related to cisplatin resistance showed a direct correlation between cisplatin and lipoplatin resistance and ERCC1 and LRP expression. Cisplatin 70-79 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 167-172 18623378-1 2008 BACKGROUND: Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC). Cisplatin 114-123 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 18483312-8 2008 ERCC1-mediated reduction in NER functionality affects the repair of cisplatin-DNA lesions. Cisplatin 68-77 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 18594541-0 2008 ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Cisplatin 101-110 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 18594541-2 2008 The purpose of this study was to evaluate the role of ERCC1 expression as a predictive marker of survival in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) treated with cisplatin-based concurrent chemoradiotherapy (CCRT). Cisplatin 206-215 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 54-59 18594541-10 2008 These results suggest that ERCC1 expression might be a useful predictive marker of locally advanced SCCHN in patients treated with cisplatin-based CCRT. Cisplatin 131-140 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 18425336-2 2008 It has recently been proposed that a synonymous polymorphism at codon 118 converting a common codon usage (AAC) to an infrequent one (AAT) may impair ERCC1 translation and to affect the response to cisplatin chemotherapy. Cisplatin 198-207 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 150-155 18640939-1 2008 PURPOSE: We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall survival (OS) in women with optimally resected, stage III epithelial ovarian cancer (EOC) treated with cisplatin and paclitaxel (C+P). Cisplatin 348-357 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 101-106 18347182-2 2008 Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing 1 (ERCC1), and cytidine deaminase (CDA) genes have been associated with alterations in enzymatic activity and may change sensitivity to the widely used cisplatin-gemcitabine regimen. Cisplatin 246-255 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 58-95 19578506-4 2008 Many reports have explored the role of the excision repair cross-complementation group 1 enzyme (ERCC1) expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells.Using immunohistochemistry in resected tumors from patients included in the International Adjuvant Lung Cancer Trial, the study of important biomarkers showed that high ERCC1 protein expression was associated with improved survival in chemo-naive patients. Cisplatin 142-151 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 43-95 19578506-4 2008 Many reports have explored the role of the excision repair cross-complementation group 1 enzyme (ERCC1) expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells.Using immunohistochemistry in resected tumors from patients included in the International Adjuvant Lung Cancer Trial, the study of important biomarkers showed that high ERCC1 protein expression was associated with improved survival in chemo-naive patients. Cisplatin 142-151 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-102 19578506-5 2008 On the contrary, the benefit of adjuvant cisplatin-based chemotherapy was more profound in patients with low ERCC1 expression. Cisplatin 41-50 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 109-114 19578506-6 2008 In a prospective cohort studying mRNA expression in tumor biopsies from patients receiving customized therapy with cisplatin and gemcitabine depending on the molecular profile of the tumour, results showed that patients with low ERCC1 mRNA expression had a longer median survival compared to those with high expression. Cisplatin 115-124 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 229-234 18402708-0 2008 ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 18402708-3 2008 To investigate their potential role in serving as biomarkers for drug sensitivity in cancer patients with metastases, we statistically measure the mRNA expression level of ERCC1 and BRCA1 in tumor cells isolated from malignant effusions and correlate them with cisplatin and/or docetaxel chemosensitivity. Cisplatin 261-270 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 172-177 18402708-6 2008 RESULTS: ERCC1 expression level is negatively correlated with the sensitivity to cisplatin in NSCLC patients (P = 0.001). Cisplatin 81-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-14 18402708-8 2008 A significant interaction is found between ERCC1 and BRCA1 mRNA expressions on sensitivity to cisplatin (P = 0.010, n = 45). Cisplatin 94-103 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 43-48 18402708-9 2008 CONCLUSION: Our results demonstrate that ERCC1 and BRCA1 mRNA expression levels are correlated with in vitro chemosensitivity to cisplatin and/or docetaxel in malignant effusions of NSCLC and gastric cancer patients. Cisplatin 129-138 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 18402708-10 2008 And combination of ERCC1 and BRCA1 may have a better role on predicting the sensitivity to cisplatin than the single one is considered. Cisplatin 91-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 18347182-2 2008 Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing 1 (ERCC1), and cytidine deaminase (CDA) genes have been associated with alterations in enzymatic activity and may change sensitivity to the widely used cisplatin-gemcitabine regimen. Cisplatin 246-255 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-102 21885003-5 2008 Several layers of evidence indicate that ERCC1 mRNA expression could be a predictive marker for cisplatin alone or in combination with certain drugs such as etoposide, gemcitabine, and 5-fluorouracil but not in combination with antimicrotubule drugs. Cisplatin 96-105 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 18645262-9 2008 CONCLUSION: The ZNRD1 gene might be involved in the cisplatin resistance of EC109 cells by regulating the expression of ERCC1 and Bcl-2. Cisplatin 52-61 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 120-125 17905465-0 2008 ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 17905465-1 2008 The excision repair cross-complementation group 1 (ERCC1) and BRCA1 have been identified as predictors of clinical outcomes among patients with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. Cisplatin 192-201 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 4-49 17905465-1 2008 The excision repair cross-complementation group 1 (ERCC1) and BRCA1 have been identified as predictors of clinical outcomes among patients with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. Cisplatin 192-201 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 51-56 17905465-7 2008 In summary, we showed that a ERCC1-negative protein status was significantly related to tumor responsiveness to neoadjuvant chemotherapy with cisplatin and irinotecan, but such a status was not a clear prognostic predictor to cisplatin-based neoadjuvant therapy in NSCLC patients. Cisplatin 142-151 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 29-34 18756932-0 2008 [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer]. Cisplatin 78-87 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 54-59 18756932-1 2008 OBJECTIVE: To study the relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer. Cisplatin 101-110 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 77-82 18756932-2 2008 METHODS: The expression of gene ERCC1 in 58 ovarian cancer tissues and 4 cell lines were examined and its relationship with resistance to cisplatin were analyzed, the changes of sensitivity to cisplatin were observed after interference of ERCC1 gene with small interfering RNA (siRNA) in ovarian cancer cell lines. Cisplatin 193-202 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 32-37 18756932-2 2008 METHODS: The expression of gene ERCC1 in 58 ovarian cancer tissues and 4 cell lines were examined and its relationship with resistance to cisplatin were analyzed, the changes of sensitivity to cisplatin were observed after interference of ERCC1 gene with small interfering RNA (siRNA) in ovarian cancer cell lines. Cisplatin 193-202 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 239-244 18756932-4 2008 The mRNA levels of ERCC1 gene in ovarian cancer cell lines ES-2, SKOV3, COC1, COC1/DDP were related to cisplatin IC50 values (r = 0.932, P <0.05). Cisplatin 103-112 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 18756932-5 2008 The sensitivity of cell lines ES-2, SKOV3, COC1/DDP cells to cisplatin was increased by 53.88, 5.07, and 3.75 times, respectively, after RNA interfering ERCC1 gene. Cisplatin 61-70 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 153-158 18756932-6 2008 CONCLUSION: ERCC1 gene is associated with the resistance to cisplatin and the sensitivity to cisplatin can be enhanced by RNA interfering ERCC1 in ovarian cancer. Cisplatin 60-69 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-17 18756932-6 2008 CONCLUSION: ERCC1 gene is associated with the resistance to cisplatin and the sensitivity to cisplatin can be enhanced by RNA interfering ERCC1 in ovarian cancer. Cisplatin 60-69 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 138-143 18756932-6 2008 CONCLUSION: ERCC1 gene is associated with the resistance to cisplatin and the sensitivity to cisplatin can be enhanced by RNA interfering ERCC1 in ovarian cancer. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-17 18756932-6 2008 CONCLUSION: ERCC1 gene is associated with the resistance to cisplatin and the sensitivity to cisplatin can be enhanced by RNA interfering ERCC1 in ovarian cancer. Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 138-143 18231104-5 2008 In patients given first-line cisplatin-based regimens (combined with S-1 or irinotecan) (43 patients), low ERCC1 correlated with a higher response rate (low: 55.6% vs high: 18.8%; P=0.008). Cisplatin 29-38 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-112 17953711-6 2008 ERCC1, a structure-specific endonuclease involved in nucleotide excision repair (NER) and HR, confers resistance to cisplatin. Cisplatin 116-125 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 17953711-7 2008 Patients with ERCC1-negative non-small-cell lung cancer were shown to benefit from adjuvant cisplatin-based chemotherapy. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 18235415-5 2007 In this review, we will discuss the potential of ERCC1 (excision repair cross complementary group 1) to predict sensitivity to cisplatinum, of tubuline-beta, class III for vinca-alkaloids and taxanes, RRM1 (ribonucleotide transferase subunit 1) for gemcitabine and lastly demographic parameters as well biological parameters for erlotinib. Cisplatin 127-138 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 49-54 21126401-0 2007 [Relationship between ERCC1 expression and cisplatin intervention in human lung adenocarcinoma cell lines]. Cisplatin 43-52 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 22-27 21126401-1 2007 BACKGROUND: The excision repair cross-complementing gene 1 (ERCC1), which is important in the repair of cisplatin-DNA adducts, is reported to be related to cisplatin resistance in tumor cells. Cisplatin 104-113 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 16-58 21126401-1 2007 BACKGROUND: The excision repair cross-complementing gene 1 (ERCC1), which is important in the repair of cisplatin-DNA adducts, is reported to be related to cisplatin resistance in tumor cells. Cisplatin 104-113 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 60-65 21126401-1 2007 BACKGROUND: The excision repair cross-complementing gene 1 (ERCC1), which is important in the repair of cisplatin-DNA adducts, is reported to be related to cisplatin resistance in tumor cells. Cisplatin 156-165 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 16-58 21126401-1 2007 BACKGROUND: The excision repair cross-complementing gene 1 (ERCC1), which is important in the repair of cisplatin-DNA adducts, is reported to be related to cisplatin resistance in tumor cells. Cisplatin 156-165 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 60-65 21126401-2 2007 The aim of this study is to investigate the influence of low-dose cisplatin on expression of ERCC1 gene and to confirm the correlation between ERCC1 and cisplatin resistance in human lung adenocarcinoma cell lines. Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 93-98 21126401-2 2007 The aim of this study is to investigate the influence of low-dose cisplatin on expression of ERCC1 gene and to confirm the correlation between ERCC1 and cisplatin resistance in human lung adenocarcinoma cell lines. Cisplatin 153-162 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 143-148 21126401-6 2007 RESULTS: After treating with 10 mumol/L cisplatin for 12 h, up-regulation of ERCC1 mRNA and protein was observed in A549 cells, then reached the peak levels in 72 h group. Cisplatin 40-49 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 77-82 21126401-7 2007 After treating with 5 mumol/L cisplatin for 24 h, up-regulation of ERCC1 mRNA and protein was observed in A549 cells, and when treated with 20 mumol/L cisplatin for 24 h, the ERCC1 mRNA and protein reached the peak levels. Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 67-72 21126401-7 2007 After treating with 5 mumol/L cisplatin for 24 h, up-regulation of ERCC1 mRNA and protein was observed in A549 cells, and when treated with 20 mumol/L cisplatin for 24 h, the ERCC1 mRNA and protein reached the peak levels. Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 175-180 21126401-7 2007 After treating with 5 mumol/L cisplatin for 24 h, up-regulation of ERCC1 mRNA and protein was observed in A549 cells, and when treated with 20 mumol/L cisplatin for 24 h, the ERCC1 mRNA and protein reached the peak levels. Cisplatin 151-160 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 67-72 21126401-7 2007 After treating with 5 mumol/L cisplatin for 24 h, up-regulation of ERCC1 mRNA and protein was observed in A549 cells, and when treated with 20 mumol/L cisplatin for 24 h, the ERCC1 mRNA and protein reached the peak levels. Cisplatin 151-160 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 175-180 21126401-8 2007 Comparing with the parental cells, ERCC1 expression increased obviously in A549/DDP cells, which were established by continuous low-dose cisplatin treatment. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 21126401-9 2007 CONCLUSIONS: Up-regulation of ERCC1 expression can be induced by low-dose cisplatin in human lung adenocarcinoma cell line A549, and ECRR1 may play roles in cisplatin resistance. Cisplatin 74-83 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-35 21126401-9 2007 CONCLUSIONS: Up-regulation of ERCC1 expression can be induced by low-dose cisplatin in human lung adenocarcinoma cell line A549, and ECRR1 may play roles in cisplatin resistance. Cisplatin 157-166 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-35 17534174-3 2007 Many reports have explored the role of ERCC1 expression in the repair mechanism of cisplatin-induced DNA adducts in cancer cells. Cisplatin 83-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-44 19190690-0 2007 ERCC1 Expression in Diffuse Large B-Cell Lymphoma Patients Treated with a Cisplatin-Based Regimen : A Brief Communication. Cisplatin 74-83 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 19190690-2 2007 Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer. Cisplatin 87-96 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-34 19190690-2 2007 Excision repair cross complement 1 (ERCC1) enzyme has been shown to predict benefit of cisplatin in different types of cancer. Cisplatin 87-96 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-41 19190690-7 2007 Key Words : ERCC1 -Large B-cell lymphoma -Cisplatin resistance. Cisplatin 42-51 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-17 17686445-3 2007 Expression of markers of DNA repair, ERCC1, RRM1 and BRCA1 are also determinants of response to cisplatin/gemcitabine, with low levels of mRNA predicting improved survival. Cisplatin 96-105 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 17606717-0 2007 Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Cisplatin 157-166 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-45 17606717-1 2007 PURPOSE: To assess the correlation of excision repair cross complementation group 1 (ERCC1) immunohistochemical expression with objective tumor response and cancer-specific survival in patients with locally advanced head and neck squamous cell carcinoma treated with cisplatin-based induction chemotherapy. Cisplatin 267-276 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-83 17606717-1 2007 PURPOSE: To assess the correlation of excision repair cross complementation group 1 (ERCC1) immunohistochemical expression with objective tumor response and cancer-specific survival in patients with locally advanced head and neck squamous cell carcinoma treated with cisplatin-based induction chemotherapy. Cisplatin 267-276 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 85-90 17606717-10 2007 CONCLUSION: Our results suggest that those patients characterized by low ERCC1 expression are more likely to benefit from cisplatin induction chemotherapy compared with patients with high ERCC1 expression. Cisplatin 122-131 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 73-78 17534174-5 2007 In contrast, the benefit of adjuvant cisplatin-based chemotherapy was more profound in patients with low ERCC1 expression. Cisplatin 37-46 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 105-110 17534174-6 2007 Other investigators studying mRNA expression in tumor biopsies from patients treated with cisplatin and gemcitabine showed that patients with low ERCC1 mRNA expression have a longer median survival compared to those with high expression. Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 146-151 17602080-0 2007 Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. Cisplatin 12-21 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-81 17602080-12 2007 CONCLUSION: Assessment of ERCC1 mRNA expression in patient tumor tissue is feasible in the clinical setting and predicts response to docetaxel and cisplatin. Cisplatin 147-156 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 26-31 17602080-2 2007 Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-37 17602080-2 2007 Excision repair cross-complementing 1 (ERCC1) has been associated with cisplatin resistance. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-44 17602080-3 2007 We hypothesized that assigning cisplatin based on pretreatment ERCC1 mRNA levels would improve response. Cisplatin 31-40 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 63-68 17151930-1 2007 ERCC1 and ERCC2 have been known to belong to the nucleotide excision repair (NER) pathway and are essential to the repair of cisplatin DNA adducts. Cisplatin 125-134 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 17489733-13 2007 Overall, the data suggest that ERCC1 is a marker for resistance to cisplatin. Cisplatin 67-76 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-36 17151930-9 2007 Further more, tumor samples with low ERCC1 mRNA expression levels showed enhanced CDDP cytotoxicity (P = 0.0001) while ERCC2 expression was reversely correlated with BCNU cytotoxicity (P = 0.004). Cisplatin 82-86 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 17151930-10 2007 In sum, Our results indicated that ERCC1 mRNA expression is associated with CDDP cytotoxicity and ERCC2 mRNA levels is related with BCNU cytotoxicity, while there was no correlation between SNP of ERCC1, ERCC2 and in vitro cytotoxicity of four anticancer drugs, CDDP, BCNU, VCR and VM26. Cisplatin 76-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 16756962-3 2006 Downregulation of ERCC1 sensitised DU145 and PC3 cells to cisplatin and mitomycin C. Cisplatin 58-67 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 17600754-9 2007 In patients with early stage NSCLC, low ERCC1 predicts for relapse and selects for patients who will benefit from adjuvant cisplatin-based chemotherapy. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 40-45 17607914-7 2007 Analysis of the expression of 5-fluorouracil (5-FU) (TS, DPD, TP)- and cisplatin (ERCC1, ERCC4, GADD45A, KU80)-related genes demonstrated an association of DPD expression with response and survival. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 16980606-0 2006 ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Cisplatin 132-141 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 16980606-8 2006 Among cisplatin-treated patients, a low ERCC1 level was highly predictive of a longer survival (23.0 versus 12.4, P = 0.0001 log-rank test). Cisplatin 6-15 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 40-45 16980606-12 2006 CONCLUSIONS: This retrospective study further validates ERCC1 and RRM1 genes as reliable candidates for customized chemotherapy and shows a higher impact on the survival of NSCLC patients treated with cisplatin/gemcitabine for ERCC1. Cisplatin 201-210 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 56-61 16980606-12 2006 CONCLUSIONS: This retrospective study further validates ERCC1 and RRM1 genes as reliable candidates for customized chemotherapy and shows a higher impact on the survival of NSCLC patients treated with cisplatin/gemcitabine for ERCC1. Cisplatin 201-210 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 227-232 16690105-7 2006 In the gemcitabine plus cisplatin treatment arm compared to either alone, there was also downregulation of MSH2, p53, and ERCC1 expression. Cisplatin 24-33 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 122-127 16690105-11 2006 Downregulation of MSH2, p53 and ERCC1 expression may also contribute to increase cytotoxic activity compared to cisplatin alone. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 32-37 17229776-0 2007 Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Cisplatin 100-109 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 18157593-3 2007 Patients with an elevated DNA repair capacity, indicated by an increased tumoral expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotid reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively. Cisplatin 216-225 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-140 18157593-3 2007 Patients with an elevated DNA repair capacity, indicated by an increased tumoral expression of excision repair cross complementation group-1 (ERCC1) or ribonucleotid reductase subunit M1 (RRM1) may benefit less from cisplatin-based and gemcitabine-based chemotherapy, respectively. Cisplatin 216-225 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 142-147 16957145-0 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. Cisplatin 54-63 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 16957145-6 2006 A benefit from cisplatin-based adjuvant chemotherapy was associated with the absence of ERCC1 (test for interaction, P=0.009). Cisplatin 15-24 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-93 16957145-9 2006 CONCLUSIONS: Patients with completely resected non-small-cell lung cancer and ERCC1-negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy, whereas patients with ERCC1-positive tumors do not. Cisplatin 132-141 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 78-83 16935774-5 2006 Secondly, single nucleotide polymorphisms in the ERCC1 gene influence survival and toxicity with cisplatin-based chemotherapy. Cisplatin 97-106 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 49-54 16765644-5 2006 mRNA transcripts involved in DNA repair pathways, such as ERCC1 and BRCA1, confer selective resistance to cisplatin or taxanes, whereas thioredoxin confers a broad spectrum of chemoresistance. Cisplatin 106-115 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 58-63 16756962-6 2006 Excision repair of cisplatin adducts in PC3 cells was attenuated to a similar extent by XPA and ERCC1 downregulation. Cisplatin 19-28 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 96-101 16756962-8 2006 We observed co-localisation of ERCC1 and RAD51 in cisplatin treated PC3 cells by immunofluorescence and co-immunoprecipitation, which may represent recruitment of ERCC1/XPF to sites of recombination repair. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-36 16756962-8 2006 We observed co-localisation of ERCC1 and RAD51 in cisplatin treated PC3 cells by immunofluorescence and co-immunoprecipitation, which may represent recruitment of ERCC1/XPF to sites of recombination repair. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 163-168 16426580-2 2006 Overexpression of ERCC1 through promoter-mediating transcriptional regulation is associated with repair of cisplatin-induced DNA damage and clinical resistance to platinum-chemotherapy. Cisplatin 107-116 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 16762192-1 2006 OBJECTIVE: To study changes of cisplatin sensitivity by RNA interfering the excision repair cross-complementing (ERCC) 1 gene in ovarian cancer cell lines. Cisplatin 31-40 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 76-120 16762192-6 2006 The sensitivity to cisplatin of ES-2 cell line was increased by 53.88 times after disturbing the ERCC1 gene. Cisplatin 19-28 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-102 16762192-7 2006 CONCLUSION: The sensitivity to cisplatin of ovarian cancer cell lines ES-2 could be enhanced by RNA interfering ERCC1 gene. Cisplatin 31-40 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 112-117 16426580-9 2006 Overexpression of MZF1 repressed the ERCC1 promoter activity as determined in co-transfection assay, suggesting that MZF1 might be a repressor of ERCC1 transcription upon cisplatin exposure. Cisplatin 171-180 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 16426580-9 2006 Overexpression of MZF1 repressed the ERCC1 promoter activity as determined in co-transfection assay, suggesting that MZF1 might be a repressor of ERCC1 transcription upon cisplatin exposure. Cisplatin 171-180 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 146-151 16426580-12 2006 In response to cisplatin treatment, decreased MZF1 and increased AP1 binding activities appear to be the leading mechanism of up-regulation of ERCC1 expression. Cisplatin 15-24 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 143-148 19771254-1 2006 PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. Cisplatin 150-159 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-98 16462182-3 2006 Single nucleotide polymorphisms in the excision repair cross-complementing 1 gene (ERCC1) influence survival with cisplatin-based chemotherapy. Cisplatin 114-123 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 83-88 19771254-1 2006 PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. Cisplatin 150-159 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 100-105 19771254-1 2006 PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. Cisplatin 161-165 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-98 19771254-1 2006 PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. Cisplatin 161-165 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 100-105 19771254-1 2006 PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. Cisplatin 223-227 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-98 19771254-1 2006 PURPOSE: It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. Cisplatin 223-227 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 100-105 19771254-9 2006 CONCLUSION: The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. Cisplatin 73-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 200-205 16632419-4 2006 mRNA transcripts involved in DNA repair pathways, such as ERCC1 and BRCA1, confer selective resistance to cisplatin or taxanes. Cisplatin 106-115 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 58-63 16551521-8 2005 We report here our accumulated experience of ERCC1 mRNA expression and outcome in cisplatin-treated NSCLC patients and the preliminary confirmatory data on a prospective ERCC1 mRNA customized docetaxel-cisplatin trial, in which low ERCC1 mRNA levels in the tumor correlate with significantly better response. Cisplatin 82-91 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 17163161-7 2006 Analysis of expression of 5-FU-(e.g., TS, DPD, and TP) and cisplatin-(e.g., ERCC1, ERCC4, GADD45A, and KU80) related genes, demonstrated an association of DPD expression with response and survival. Cisplatin 59-68 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 76-81 17303907-1 2006 A few reports for ERCC1 SNPs were conducted in patients treated with cisplatin chemotherapy. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 17303907-8 2006 These findings may suggest that the ERCC1 118 SNP is an useful prognostic factor related to cisplatin therapy and the effect of this polymorphism appears to be modified by smoking. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-41 16557672-10 2005 ERCC1 is one of several proteins involved in the repairosome, where other DNA repair genes, such as BRCA1, are also central to cisplatin resistance. Cisplatin 127-136 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 16551521-9 2005 ERCC1 is one of several proteins involved in the repairosome, where other DNA repair genes, such as BRCA1, are also central to cisplatin resistance. Cisplatin 127-136 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 16557672-9 2005 We report here our accumulated experience of ERCC1 mRNA expression and outcome in cisplatin-treated NSCLC patients and the preliminary confirmatory data on a prospective ERCC1 mRNA customized docetaxel-cisplatin trial, in which low ERCC1 mRNA levels in the tumor correlate with significantly better response. Cisplatin 82-91 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 15375562-8 2004 We conclude that the 42-bp sequence within the 5"-UTR influences the expression of ERCC1 and hence can influence response to cisplatin in ovarian cancer therapy. Cisplatin 125-134 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 83-88 15688021-2 2005 One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. Cisplatin 58-67 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 169-174 15688021-3 2005 Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Cisplatin 54-63 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 121-126 15688021-3 2005 Since 30-40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Cisplatin 208-217 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 121-126 15629453-1 2005 The level of excision repair cross-complementing 1 (ERCC1) gene expression, which is important in the repair of the cisplatin-DNA adducts, is reported to be related to the level of cisplatin resistance in tumor cells. Cisplatin 116-125 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 52-57 15629453-1 2005 The level of excision repair cross-complementing 1 (ERCC1) gene expression, which is important in the repair of the cisplatin-DNA adducts, is reported to be related to the level of cisplatin resistance in tumor cells. Cisplatin 181-190 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-50 15629453-1 2005 The level of excision repair cross-complementing 1 (ERCC1) gene expression, which is important in the repair of the cisplatin-DNA adducts, is reported to be related to the level of cisplatin resistance in tumor cells. Cisplatin 181-190 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 52-57 15629453-2 2005 Therefore, ERCC1 is an attractive target to confer increased cellular sensitivity to cisplatin-based chemotherapy. Cisplatin 85-94 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 11-16 15629453-5 2005 The suppression of ERCC1 expression in the HeLa S3 cells led to a decrease in the repair activity of cisplatin-induced DNA damage along with a decrease in the cell viability against platinum-based drugs, such as cisplatin, carboplatin, and oxaliplatin. Cisplatin 101-110 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 15629453-5 2005 The suppression of ERCC1 expression in the HeLa S3 cells led to a decrease in the repair activity of cisplatin-induced DNA damage along with a decrease in the cell viability against platinum-based drugs, such as cisplatin, carboplatin, and oxaliplatin. Cisplatin 212-221 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 15629453-6 2005 A similar increased sensitivity to cisplatin and decreased repair activity were also observed for siRNA-mediated ERCC1 silencing in the MCF-7 and HCT116 cells. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 113-118 15629453-0 2005 Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Cisplatin 97-106 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 15629453-1 2005 The level of excision repair cross-complementing 1 (ERCC1) gene expression, which is important in the repair of the cisplatin-DNA adducts, is reported to be related to the level of cisplatin resistance in tumor cells. Cisplatin 116-125 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-50 15547660-6 2004 In this report we reviewed the pathway leading to ERCC1 gene transcription and translation in cancer cells when exposed to cisplatin. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-55 15277258-2 2004 Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Cisplatin 161-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-37 15277258-4 2004 We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel-cisplatin-treated stage IV NSCLC patients. Cisplatin 148-157 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 93-98 15277258-2 2004 Excision-repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) are essential to the repair of cisplatin DNA adducts. Cisplatin 161-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-44 15277258-4 2004 We assessed whether single nucleotide polymorphisms (SNPs) in ERCC1, XPD, RRM1 and MDR1, and ERCC1 mRNA expression, predicted survival in docetaxel-cisplatin-treated stage IV NSCLC patients. Cisplatin 148-157 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 62-67 14706347-5 2004 These data suggest that ERCC1 and MSH2 are involved co-operatively in CDDP resistance in mammalian cells. Cisplatin 70-74 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 15248926-2 2004 The purpose of this study was to evaluate the relationship of the cisplatin sensitivity/prognosis with the expression of excision repair cross complement-1 (ERCC-1), metallothionein (MT), and p53 in the paraffin-embedded tissue of advanced non-small cell lung cancer (NSCLC). Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 121-155 15248926-2 2004 The purpose of this study was to evaluate the relationship of the cisplatin sensitivity/prognosis with the expression of excision repair cross complement-1 (ERCC-1), metallothionein (MT), and p53 in the paraffin-embedded tissue of advanced non-small cell lung cancer (NSCLC). Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 157-163 15248926-17 2004 CONCLUSION: Whether over-expression of ERCC-1 and MT can be used as a molecular marker of cisplatin resistance in advanced NSCLC patients need further study. Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-45 15140544-0 2004 Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Cisplatin 116-125 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 15140544-10 2004 Therefore, we suggest that the C/C genotype in codon 118 of ERCC1 is a surrogate marker for predicting better survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Cisplatin 171-180 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 60-65 14977831-2 2004 Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Cisplatin 199-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 122-165 14977831-2 2004 Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Cisplatin 199-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 167-172 14706347-0 2004 Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. Cisplatin 88-116 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 14706347-3 2004 By using RNA interference we show here that suppression of ERCC1 expression increases the sensitivity of xeroderma pigmentosum group A (XPA)-deficient human cells to CDDP but not to UV. Cisplatin 166-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 14706347-8 2004 This interaction may be important in additional functions of ERCC1-XPF including the repair of CDDP-induced DNA damage. Cisplatin 95-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-66 14981577-3 2004 Within the global genomic repair pathway, overexpression of excision repair cross-complementing 1 (ERCC1) has been associated with poor response and survival in cisplatin-treated patients. Cisplatin 161-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 60-97 14981577-3 2004 Within the global genomic repair pathway, overexpression of excision repair cross-complementing 1 (ERCC1) has been associated with poor response and survival in cisplatin-treated patients. Cisplatin 161-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 99-104 12917817-5 2003 Overexpression of ERCC1 correlates with poor survival in gemcitabine/cisplatin-treated non-small cell lung cancer patients. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 14668933-10 2003 Overexpression of ERCC1 correlates with poor survival gemcitabine/cisplatin-treated non-small cell lung cancer patients. Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 14668933-19 2003 Preliminary findings indicate that a subset of gemcitabine/cisplatin-treated patients with low ERCC1 and RRM1 mRNA levels show a significantly longer survival. Cisplatin 59-68 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 12867068-10 2003 Overexpression of ERCC1 correlates with poor survival in gemcitabine/cisplatin-treated NSCLC patients. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 12917817-11 2003 Preliminary findings that a subset of gemcitabine/cisplatin-treated patients with low ERCC1 and RRM1 mRNA levels show a significantly longer survival and highlight the possibilities of individually tailored chemotherapy. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-91 12445742-6 2002 Some DNA repair genes, like ERCC1, have been shown to be crucial in predicting cisplatin resistance and can be used for tailoring cisplatin-based chemotherapy. Cisplatin 79-88 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 28-33 12504621-2 2003 Platinum resistance is related to expression of excision repair proteins, one of which (ERCC-1) has been identified as playing a critical role in the synergy of gemcitabine and cisplatin. Cisplatin 177-186 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-94 12915808-5 2003 RESULTS: ERCC1 is a single-stranded DNA endonuclease that forms a tight heterodimer with xeroderma pigmentosum complementation group F. It incises DNA on the 5" side of a lesion such as cisplatin-DNA adduct. Cisplatin 186-195 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-14 12915808-6 2003 Therefore, overexpression of ERCC1 and other NER enzymes during ovarian cancer chemotherapy with cisplatin appears to be implicated in the formation of cellular and clinical drug resistance. Cisplatin 97-106 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 29-34 12915808-7 2003 Recently, baseline ERCC1 mRNA overexpression has been related to poor response and survival in cisplatin-treated NSCLC patients. Cisplatin 95-104 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 12649192-5 2003 Expression of one of the NER components, ERCC1, is correlated with cisplatin drug resistance. Cisplatin 67-76 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 12649192-6 2003 Hence, we targeted ERCC1 by antisense RNA methodologies, and we show that we could sensitize a relatively sensitive A2780 cell line and also the highly resistant OVCAR10 cell line to cisplatin by expressing antisense ERCC1 RNA in them as measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Cisplatin 183-192 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 12649192-6 2003 Hence, we targeted ERCC1 by antisense RNA methodologies, and we show that we could sensitize a relatively sensitive A2780 cell line and also the highly resistant OVCAR10 cell line to cisplatin by expressing antisense ERCC1 RNA in them as measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays. Cisplatin 183-192 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 217-222 12649192-7 2003 The A2780 cell lines expressing antisense ERCC1 had 1.9-8.1-fold enhancements in cisplatin sensitivity. Cisplatin 81-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 42-47 12649192-8 2003 The OVCAR10 antisense ERCC1 cell lines had IC(50) values ranging from 2.28 microM to 2.7 microM cisplatin as compared with 9.52 micro M for control OVCAR10 cells. Cisplatin 96-105 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 22-27 14624713-5 2003 ERCC1 overexpression has been associated with cisplatin resistance, and experimental evidence shows a close association between ERCC1 and XPD. Cisplatin 46-55 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 12359362-4 2002 Quantitative real-time reverse transcription polymerase chain reaction analysis revealed that cisplatin treatment of K562 cells resulted in a 1.9-fold increase in mRNA expression of the nucleotide excision repair gene ERCC-1. Cisplatin 94-103 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 218-224 12480194-2 2002 Preliminary findings are that non-small cell lung cancer patients overexpressing ERCC1 mRNA have lower response to cisplatin chemotherapy, while those overexpressing ribonucleotide reductase mRNA have limited benefit from gemcitabine. Cisplatin 115-124 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 81-86 12445742-6 2002 Some DNA repair genes, like ERCC1, have been shown to be crucial in predicting cisplatin resistance and can be used for tailoring cisplatin-based chemotherapy. Cisplatin 130-139 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 28-33 11008124-0 2000 Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Cisplatin 40-49 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 90-95 12437479-5 2002 ERCC1 gene transcript stands out as a predictive marker of cisplatin sensitivity. Cisplatin 59-68 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 12114432-1 2002 PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Cisplatin 128-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-68 12114432-1 2002 PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Cisplatin 128-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 70-75 12114432-1 2002 PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Cisplatin 204-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-68 12114432-1 2002 PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Cisplatin 204-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 70-75 12114432-2 2002 Recent evidence indicates that Gemcitabine (Gem) may modulate ERCC1 nucleotide excision repair activity, and down-regulation of DNA repair activity by ERCC1 antisense RNA reportedly inhibits synergism of CDDP/Gem. Cisplatin 204-208 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 151-156 12114432-12 2002 CONCLUSIONS: These data suggest that ERCC1 expression is a predictive factor for survival after CDDP/Gem therapy in advanced NSCLC. Cisplatin 96-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 12114432-14 2002 This result may reflect the impact of Gem and the requirement for ERCC1 expression for CDDP/Gem synergism or may be attributable to the relatively small patient sample size in this study. Cisplatin 87-91 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 12114432-15 2002 Prospective studies of ERCC1 as a predictive marker for activity of CDDP-based regimens in NSCLC are warranted. Cisplatin 68-72 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 23-28 12023789-7 2002 The assessment of TS levels and ERCC1 as a marker of cisplatin resistance is leading to customized chemotherapy. Cisplatin 53-62 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 32-37 11761458-12 2001 Exposure to either one of the drugs resulted in an induction of XPA in all the cell lines and of ERCC-1 in cisplatin-resistant cells. Cisplatin 107-116 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-103 11605182-13 2001 Cisplatin resistance is associated with several molecular alterations, including overexpression of metallothionein and the mRNA level of the excision repair cross-complementing (ERCC1) gene. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 178-183 11163512-3 2001 ERCC1 expression has also been shown to be upregulated by cisplatin exposure. Cisplatin 58-67 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 11163512-8 2001 RESULTS: In the cisplatin-sensitive non-small-cell lung cancer cell line, ERCC1 expression at the mRNA or protein level was not significantly altered in any of the treatment groups. Cisplatin 16-25 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 74-79 11163512-9 2001 In the cisplatin-resistant ovarian cancer cell line, ERCC1 expression was upregulated by TPZ, but not by cisplatin alone. Cisplatin 7-16 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 53-58 11163512-9 2001 In the cisplatin-resistant ovarian cancer cell line, ERCC1 expression was upregulated by TPZ, but not by cisplatin alone. Cisplatin 105-114 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 53-58 12114432-0 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Cisplatin 62-71 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 4-9 12114432-1 2002 PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-68 12114432-1 2002 PURPOSE: Overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is crucial in the repair of cisplatin (CDDP)-DNA adducts, is reported to negatively influence the effectiveness of CDDP-based therapy for gastric and ovarian cancers. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 70-75 11163512-2 2001 Cisplatin sensitivity has been shown to be dependent on the expression of the two DNA repair proteins ERCC1 and XPA. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 102-107 11008124-4 2000 Northern blot analysis revealed that increased expression of ERCC1 was also associated with cisplatin resistance in this panel. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-66 11008124-9 2000 Overall, these results support a role for the ERCC1-XPF endonuclease as a determinant of increased NER in this cisplatin resistance model. Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 46-51 11008128-6 2000 Both proteasome inhibitors also prevented the increase in ERCC-1 mRNA expression that occurs in cells exposed to cisplatin. Cisplatin 113-122 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 58-64 10810335-0 2000 Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 33-39 11008208-0 2000 ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Cisplatin 42-51 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 11008208-4 2000 We investigated whether high pre-treatment mRNA levels of the ERCC1 nucleotide excision repair gene are predictive of cisplatin resistance in early-passage human cervical cancer cells, as they are in several other tumor types. Cisplatin 118-127 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 62-67 11008208-5 2000 Expression of the ERCC1 gene at the mRNA and protein levels was established by Northern and Western blotting, respectively, in a panel of single-cell-derived cervical carcinoma cell lines that exhibited a wide range of inherent sensitivity to cisplatin. Cisplatin 243-252 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 11008208-6 2000 There was a significant (p </= 0.011) correlation between ERCC1 mRNA levels and cisplatin resistance in these cell lines. Cisplatin 83-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-66 11008208-8 2000 Thus, the association between high ERCC1 mRNA levels and cisplatin resistance might be an epiphenomenon. Cisplatin 57-66 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 11008208-9 2000 Nonetheless, pre-treatment ERCC1 mRNA levels may be a useful molecular marker for identifying cervical tumors likely to be refractory to cisplatin, and further investigation in clinical biopsy material is warranted. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 11589365-0 2000 Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells. Cisplatin 33-42 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 53-59 11589365-6 2000 In this communication, we demonstrate that treatment of A2780/CP70 cells with ALLnL blocks cisplatin-induced ERCC-1 mRNA expression in a concentration- and time-dependent manner, as measured by Northern blot analysis. Cisplatin 91-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 109-115 11589365-7 2000 In addition, we showed that the cisplatin-dependent increase in steady-state levels of ERCC-1 mRNA was prevented by pretreatment with lactacystin, a potent and specific inhibitor of proteasome. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 87-93 11589365-8 2000 These results suggest that the effect of proteasome inhibition on cisplatin cytotoxicity, DNA platination, and DNA repair of cisplatin adducts in ovarian cancer cells may be through down-regulating ERCC-1 expression. Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 198-204 11589365-8 2000 These results suggest that the effect of proteasome inhibition on cisplatin cytotoxicity, DNA platination, and DNA repair of cisplatin adducts in ovarian cancer cells may be through down-regulating ERCC-1 expression. Cisplatin 125-134 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 198-204 10810335-3 2000 The present study was therefore designed to evaluate the relationship between the expression of ERCC-1 and the repair of cisplatin-induced DNA adducts in human ovarian cancer cells in vitro. Cisplatin 121-130 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 96-102 10810335-4 2000 One hour exposure of MCAS cells to cisplatin yielded an approximately two-fold increment in the levels of ERCC-1 mRNA and ERCC-1 protein, as determined, respectively, by Northern and Western blottings. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 106-112 10810335-4 2000 One hour exposure of MCAS cells to cisplatin yielded an approximately two-fold increment in the levels of ERCC-1 mRNA and ERCC-1 protein, as determined, respectively, by Northern and Western blottings. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 122-128 10810335-5 2000 In addition, nuclear run-on assay showed that ERCC-1 gene transcription rate was increased to about the same extent as steady-state ERCC-1 mRNA and protein, in response to cisplatin treatment. Cisplatin 172-181 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 46-52 10810335-5 2000 In addition, nuclear run-on assay showed that ERCC-1 gene transcription rate was increased to about the same extent as steady-state ERCC-1 mRNA and protein, in response to cisplatin treatment. Cisplatin 172-181 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 132-138 10810335-7 2000 Furthermore, the repair of cisplatin-DNA adducts in MCAS cells, as measured by atomic absorption spectrometry, is also nearly two-fold less than that in A2780/CP70 cells, indicating a strong association between the level of ERCC-1 expression and the activity of excision repair in these two human ovarian tumor cell lines. Cisplatin 27-36 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 224-230 10810335-8 2000 These results suggest that ERCC-1 may be a useful marker to monitor the repair of platinum-DNA damage in tumor cells, and further highlight that potential pharmacological approaches which specifically inhibit ERCC-1 expression may increase cellular sensitivity to cisplatin. Cisplatin 264-273 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-33 10810335-8 2000 These results suggest that ERCC-1 may be a useful marker to monitor the repair of platinum-DNA damage in tumor cells, and further highlight that potential pharmacological approaches which specifically inhibit ERCC-1 expression may increase cellular sensitivity to cisplatin. Cisplatin 264-273 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 209-215 10741696-0 2000 Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Cisplatin 91-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 10675489-2 2000 We studied two human ovarian carcinoma cell lines for cisplatin resistance, which differed with respect to ERCC1. Cisplatin 54-63 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-112 9933022-6 1999 Cyclosporin A and herbimycin A, which suppress c-fos and c-jun gene expressions, respectively, blocked the cisplatin-induced increase in ERCC-1 mRNA. Cisplatin 107-116 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 137-143 9933022-7 1999 This effect of cyclosporin A or herbimycin A on the down-regulation of ERCC-1 correlates with enhanced cytotoxicity of cisplatin in this system. Cisplatin 119-128 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 71-77 9933022-2 1999 Overexpression of ERCC-1 during cisplatin-based chemotherapy is associated with clinical and cellular drug resistance. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-24 9933022-4 1999 Cisplatin exposure in culture resulted in a 4- to 6-fold induction for the steady-state level of ERCC-1 mRNA in A2780/CP70 cells. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-103 9772291-0 1998 Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 49-55 9772291-3 1998 Enhanced ERCC-1 expression has been associated with clinical and cellular resistance to cisplatin. Cisplatin 88-97 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-15 9772291-4 1998 We therefore carried out this study to investigate the effect of cisplatin on ERCC-1 protein expression in A2780/CP70 human ovarian cancer cells. Cisplatin 65-74 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 78-84 9772291-5 1998 Western blot analysis showed that ERCC-1 protein levels were increased to more than 3 times control after a 1 h cisplatin exposure to A2780/CP70 cells in culture. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 34-40 9772291-8 1998 These results extend our previous observations that ERCC-1 mRNA expression is induced by cisplatin in this system. Cisplatin 89-98 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 52-58 9852275-7 1998 These data demonstrate an association between alternative splicing of ERCC1, and reduction in cellular capability to repair cisplatin-DNA adduct. Cisplatin 124-133 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 70-75 9703867-0 1998 Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 84-90 9703867-1 1998 Enhanced expression of the human excision repair enzyme ERCC-1 is associated with cellular and clinical resistance to cisplatin in human ovarian cancer. Cisplatin 118-127 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 56-62 9703867-3 1998 We therefore began to examine the effect of some cisplatin resistance modulators on cisplatin-induced ERCC-1 mRNA expression in the human ovarian carcinoma cell line, A2780/CP70. Cisplatin 84-93 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 102-108 9703867-4 1998 Cisplatin exposure to A2780/CP70 cells in culture resulted in a four- to five-fold induction for steady-state ERCC-1 mRNA, that was dose- and time-dependent. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 110-116 9703867-6 1998 IL-1 alpha inhibited cisplatin induction of ERCC-1 mRNA levels in our system. Cisplatin 21-30 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-50 9703867-10 1998 These findings suggest that the enhancement effect of some agents on cisplatin sensitivity in ovarian tumour cells may be through downregulating ERCC-1 expression. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 145-151 9440758-0 1998 ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Cisplatin 148-157 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 9440758-3 1998 We now test the hypotheses that the relative mRNA level of the excision repair cross-complementing (ERCC1) gene is inversely associated with response and survival as an independent function of cisplatin efficacy. Cisplatin 193-202 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 100-105 34353292-9 2021 CONCLUSIONS: ERCC1 and RRM1 are useful biomarkers that predict better survival outcomes in patients with advanced MPM treated with continuous infusion of gemcitabine plus cisplatin. Cisplatin 171-180 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 21597714-4 1995 ERCC1 expression was directly related to cisplatin-DNA adduct repair capability, as well as directly related to cisplatin resistance, suggesting a primary role for ERCC1 in effecting DNA repair. Cisplatin 41-50 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21597714-4 1995 ERCC1 expression was directly related to cisplatin-DNA adduct repair capability, as well as directly related to cisplatin resistance, suggesting a primary role for ERCC1 in effecting DNA repair. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 7923602-1 1994 Previous studies have indicated that excision repair genes, such as ERCC1, or early response genes, such as c-fos, may play a significant role in regulating cellular responses to cisplatin (CDDP) by mediating DNA synthesis and repair pathways. Cisplatin 179-188 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 68-73 7923602-1 1994 Previous studies have indicated that excision repair genes, such as ERCC1, or early response genes, such as c-fos, may play a significant role in regulating cellular responses to cisplatin (CDDP) by mediating DNA synthesis and repair pathways. Cisplatin 190-194 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 68-73 8065913-0 1994 Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Cisplatin 57-66 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-24 34962119-5 2021 Thereby, the chemotherapeutic effect of CDDP could be significantly potentiated because of reduced DNA lesion repair capacity by ERCC1-XPF nuclease system. Cisplatin 40-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 129-134 34532603-2 2021 Excision repair cross-complementing group 1 (ERCC1) is involved in several repair processes of cisplatin-induced DNA crosslinks. Cisplatin 95-104 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-43 34532603-2 2021 Excision repair cross-complementing group 1 (ERCC1) is involved in several repair processes of cisplatin-induced DNA crosslinks. Cisplatin 95-104 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 34532603-3 2021 ERCC1 overexpression is reported as a candidate prognostic factor and considered to cause cisplatin resistance in major solid cancers. Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 8222071-1 1993 We assessed the possible role of the human repair genes, ERCC1 and ERCC3, in resistance to cisplatin-induced cytotoxicity. Cisplatin 91-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 57-62 33764811-0 2022 Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin. Cisplatin 216-225 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 22863869-1 2013 PURPOSE: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-61 22863869-1 2013 PURPOSE: Excision repair cross-complementation group 1 enzyme (ERCC1) plays a key role in the removal of platinum induced DNA adducts and cisplatin resistance. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 63-68 9722577-0 1998 Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 23-29 9722577-2 1998 We therefore investigated the cisplatin effect on ERCC-1 mRNA expression in vitro. Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-56 9722577-3 1998 In response to a 1-h cisplatin exposure, A2780/CP70 human ovarian cancer cells showed a 6-fold increase in steady-state level of ERCC-1 mRNA. Cisplatin 21-30 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 129-135 33487222-0 2021 Retraction notice to "The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells" [EBioMedicine 35 (2018) 204-221]. Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 46-51 33747222-3 2021 The present study aimed to explore the synergistic effects of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib combined with ERCC1 on the sensitivity of NSCLC cells to cisplatin. Cisplatin 177-186 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 134-139 33747222-9 2021 In NCI-H1299 or SK-MES-1 cells treated with cisplatin combined with olaparib for 24 h, the cell viability significantly increased following ERCC1 overexpression compared with the GV230 group (P<0.05), but significantly inhibited following ERCC1 knockdown compared with the siRNA-NC group (P<0.05). Cisplatin 44-53 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 140-145 33747222-9 2021 In NCI-H1299 or SK-MES-1 cells treated with cisplatin combined with olaparib for 24 h, the cell viability significantly increased following ERCC1 overexpression compared with the GV230 group (P<0.05), but significantly inhibited following ERCC1 knockdown compared with the siRNA-NC group (P<0.05). Cisplatin 44-53 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 239-244 33747222-11 2021 In conclusion, olaparib combined with ERCC1 expression may enhance the sensitivity of cisplatin in NSCLC. Cisplatin 86-95 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-43 33487222-0 2021 Retraction notice to "The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells" [EBioMedicine 35 (2018) 204-221]. Cisplatin 130-139 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 46-51 33266377-7 2020 Moreover, novel compounds have been recently developed to target ERCC1 protein function in order to maximize sensitivity to cisplatin. Cisplatin 124-133 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 65-70 33164868-0 2020 Sclareol ameliorated ERCC1-mediated cisplatin resistance in A549 human lung adenocarcinoma cells and a murine xenograft tumor model by suppressing AKT-GSK3beta-AP1/Snail and JNK-AP1 pathways. Cisplatin 36-45 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 21-26 32739873-11 2020 Cisplatin induces the recruitment of the ERCC1/XPF dimer to the chromatin in a TonEBP-dependent manner leading to DNA repair and cisplatin resistance. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 32173978-0 2020 Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort. Cisplatin 38-47 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 15-20 33133187-0 2020 Corrigendum to "UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells". Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 98-103 33154302-0 2020 Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 10-15 33154302-1 2020 Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. Cisplatin 27-36 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 105-150 33154302-1 2020 Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. Cisplatin 27-36 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 152-157 33154302-2 2020 The aim of this study was to investigate the association between polymorphisms in ERCC1 (C118T & C8092A) genes and the response to cisplatin-based chemotherapy. Cisplatin 131-140 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 32437713-14 2020 The luciferase assay findings showed that miR-30a-3p binds to ERCC1 and ATP7A which are the key regulators for DNA repair and cisplatin transportation. Cisplatin 126-135 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 62-67 32739873-11 2020 Cisplatin induces the recruitment of the ERCC1/XPF dimer to the chromatin in a TonEBP-dependent manner leading to DNA repair and cisplatin resistance. Cisplatin 129-138 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 32739873-12 2020 The cisplatin-induced inflammation in LSCSs is also dependent on the TonEBP-ERCC1/XPF complex, and leads to enhanced stemness via the ATM-NF-kappaB-SOX2 pathway. Cisplatin 4-13 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 76-81 32478168-0 2020 Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149. Cisplatin 88-97 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 32478168-2 2020 Overexpression of the excision repair cross-complementing 1 (ERCC1) gene is reported to negatively influence the effectiveness of cisplatin-based therapy for NSCLC cells. Cisplatin 130-139 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 22-59 32478168-2 2020 Overexpression of the excision repair cross-complementing 1 (ERCC1) gene is reported to negatively influence the effectiveness of cisplatin-based therapy for NSCLC cells. Cisplatin 130-139 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 61-66 32478168-3 2020 In this study, we confirm that high ERCC1 expression correlates with cisplatin resistance in NSCLC cells. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-41 32478168-4 2020 Importantly, histone deacetylase inhibitors (HDACis) re-sensitize ERCC1-high NSCLC cells to cisplatin both in vitro and in vivo. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 32478168-6 2020 Inhibition of miR-149 reverses the promotion effect of HDACis on cisplatin-induced DNA damage and cell apoptosis in ERCC1-high NSCLC cells. Cisplatin 65-74 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 32478168-7 2020 In conclusion, this study reveals a novel mechanism by which HDACis re-sensitizes ERCC1-high NSCLC cells to cisplatin via regulation of the E2F1/miR-149/ERCC1 axis, and we propose that combination of HDACis and cisplatin might hold promise to be a more effective therapeutic paradigm for ERCC1-high NSCLCs. Cisplatin 108-117 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 32478168-7 2020 In conclusion, this study reveals a novel mechanism by which HDACis re-sensitizes ERCC1-high NSCLC cells to cisplatin via regulation of the E2F1/miR-149/ERCC1 axis, and we propose that combination of HDACis and cisplatin might hold promise to be a more effective therapeutic paradigm for ERCC1-high NSCLCs. Cisplatin 108-117 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 153-158 32478168-7 2020 In conclusion, this study reveals a novel mechanism by which HDACis re-sensitizes ERCC1-high NSCLC cells to cisplatin via regulation of the E2F1/miR-149/ERCC1 axis, and we propose that combination of HDACis and cisplatin might hold promise to be a more effective therapeutic paradigm for ERCC1-high NSCLCs. Cisplatin 108-117 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 153-158 32478168-7 2020 In conclusion, this study reveals a novel mechanism by which HDACis re-sensitizes ERCC1-high NSCLC cells to cisplatin via regulation of the E2F1/miR-149/ERCC1 axis, and we propose that combination of HDACis and cisplatin might hold promise to be a more effective therapeutic paradigm for ERCC1-high NSCLCs. Cisplatin 211-220 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 32582340-1 2020 Background: Overexpression of excision repair cross-complementing Group 1 (ERCC-1) is related to cisplatin resistance and defective repair of radiation damage. Cisplatin 97-106 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-73 32582340-1 2020 Background: Overexpression of excision repair cross-complementing Group 1 (ERCC-1) is related to cisplatin resistance and defective repair of radiation damage. Cisplatin 97-106 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 75-81 32028591-7 2020 ERCC1 was also induced in olaparib-resistant SNU-484, SNU-601, and SNU-668, which showed cross-resistance to cisplatin. Cisplatin 109-118 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 32922493-11 2020 It can be concluded that the level of ERCC1, MLH1, MSH2, and CTR1 mRNA expression may be associated with PFS time as possible therapeutic targets for decreasing cisplatin resistance. Cisplatin 161-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-43 33747282-0 2021 Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients. Cisplatin 77-86 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 33747282-12 2021 Conclusions: SNPs in ERCC1 and TOP2 genes may be associated with the toxicities and survival of SCLC patients treated with cisplatin and etoposide. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 21-26 31586226-0 2019 Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 108-113 31586226-1 2019 PURPOSE: We aimed to investigate the cisplatin-related hearing toxicity and its possible relationship with polymorphic variants in DNA repair genes, ERCC1, ERCC2, and XRCC1. Cisplatin 37-46 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 149-154 31152437-2 2019 In particular, the elevated expression of excision repair cross-complementing 1 (ERCC1) significantly reduced the effectiveness of gastric cancer treatment by cisplatin (CDDP)-based therapies. Cisplatin 159-168 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 42-79 31152437-2 2019 In particular, the elevated expression of excision repair cross-complementing 1 (ERCC1) significantly reduced the effectiveness of gastric cancer treatment by cisplatin (CDDP)-based therapies. Cisplatin 159-168 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 81-86 31152437-2 2019 In particular, the elevated expression of excision repair cross-complementing 1 (ERCC1) significantly reduced the effectiveness of gastric cancer treatment by cisplatin (CDDP)-based therapies. Cisplatin 170-174 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 42-79 31152437-2 2019 In particular, the elevated expression of excision repair cross-complementing 1 (ERCC1) significantly reduced the effectiveness of gastric cancer treatment by cisplatin (CDDP)-based therapies. Cisplatin 170-174 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 81-86 31152437-12 2019 In summary, the reduced miR-122 expression may play an essential role in the induction of cisplatin-resistance by increasing ERCC1 expression. Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 125-130 31083486-5 2019 Significant associations were only found when using the CTCAE v4.03 definition: genotype CA of the ERCC1 rs3212986 was associated with decreased risk of cisplatin nephrotoxicity (ORadj = 0.24; 95% CI:0.08-0.70; p = 0.009) compared to genotype CC. Cisplatin 153-162 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 99-104 31772670-8 2019 Further experiments showed that the underlying mechanisms included inhibition of cisplatin-induced cell apoptosis by CLEC4M and improved DNA repair capacity by upregulating XPA and ERCC1 expression. Cisplatin 81-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 181-186 30066234-0 2019 Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine. Cisplatin 162-171 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 55-60 31083486-0 2019 Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. Cisplatin 106-115 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 80-85 30550405-5 2019 We demonstrated that docosahexenoic acid (DHA, 22:6omega-3) sensitizes the cells to the CDDP-induced inhibition of cell growth and migration by reverting CDDP effects on DNA damage and ERCC1 expression, as well as on the DUSP6 and p-ERK expressions, which regulate ERCC1 activation upwardly. Cisplatin 88-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 185-190 30550405-5 2019 We demonstrated that docosahexenoic acid (DHA, 22:6omega-3) sensitizes the cells to the CDDP-induced inhibition of cell growth and migration by reverting CDDP effects on DNA damage and ERCC1 expression, as well as on the DUSP6 and p-ERK expressions, which regulate ERCC1 activation upwardly. Cisplatin 88-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 265-270 30550405-5 2019 We demonstrated that docosahexenoic acid (DHA, 22:6omega-3) sensitizes the cells to the CDDP-induced inhibition of cell growth and migration by reverting CDDP effects on DNA damage and ERCC1 expression, as well as on the DUSP6 and p-ERK expressions, which regulate ERCC1 activation upwardly. Cisplatin 154-158 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 185-190 30550405-6 2019 In line, DUSP6 gene silencing prevented the effect of DHA, confirming that DHA acted on the DUSP6/p-ERK/ERCC1 repair pathways to sensitize melanoma cells to the anticancer effect of CDDP. Cisplatin 182-186 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 104-109 31083486-2 2019 We selected genetic variants that have been significantly associated with cisplatin-induced nephrotoxicity in more than one published study (SLC22A2 rs316019; ERCC1 rs11615 and rs3212986; ERCC2 rs1799793 and rs13181) and performed a replication analysis to confirm associations between these genetic polymorphisms and cisplatin nephrotoxicity using various outcome definitions. Cisplatin 74-83 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 159-164 30728154-2 2019 It has now been revealed that p53 mutation status should be considered concomitantly with ERCC1 to predict cisplatin efficacy.See related article by Heyza et al., p. 2523. Cisplatin 107-116 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 90-95 30538112-5 2019 RESULTS: We observe that loss of ERCC1 hypersensitizes cells to cisplatin when wild-type (WT) p53 is retained, whereas there is only modest sensitivity in cell lines that are p53mutant/null. Cisplatin 64-73 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 33-38 28918673-5 2018 Second, we showed that cisplatin-resistant A549 cells (A549/DDP) acquire EMT phenotype with high expression of drug-resistant proteins, P-gp and ERCC1. Cisplatin 23-32 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 145-150 30584903-2 2019 Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma. Cisplatin 371-380 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 55-60 30584903-2 2019 Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma. Cisplatin 371-380 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 188-193 30584903-2 2019 Since targeting excision repair cross-complementing 1 (ERCC1) may be a viable strategy to reestablish the therapeutic sensitivity to platinum-based agents in chemoresistant cases, and low ERCC1 level is beneficial to metastatic lung cancer patients undergoing platinum-based chemotherapy, we hypothesized that metastasis-associated process is involved in ERCC1-dependent cisplatin-resistance in lung adenocarcinoma. Cisplatin 371-380 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 188-193 30584903-6 2019 RESULTS: Platelet-derived growth factor receptor (PDGF/PDGFR) and focal adhesion genes were downregulated in ERCC1-defective non-small cell lung cancer (NSCLC) cells undergoing combined cisplatin/CMNa treatment. Cisplatin 186-195 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 109-114 30584903-10 2019 CONCLUSION: PDGF/PDGFR and focal adhesion signaling may serve as another mechanism in addition to ERCC1-mediated cisplatin-resistance in lung adenocarcinoma. Cisplatin 113-122 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 98-103 30668408-0 2019 Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 118-123 30563166-2 2018 Previously, DMC significantly inhibited on-target cisplatin resistance protein, ERCC1, via PI3K-Akt-snail pathways in NSCLC. Cisplatin 50-59 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 80-85 30563166-5 2018 We aimed to understand whether DMC-CHC NPs efficiently potentiate cisplatin-induced apoptosis through downregulation of ERCC1 in NSCLC. Cisplatin 66-75 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 120-125 30563166-9 2018 A combination of DMC-CHC NPs and cisplatin significantly inhibited on-target cisplatin resistance protein, ERCC1, via the PI3K-Akt pathway. Cisplatin 33-42 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-112 30563166-9 2018 A combination of DMC-CHC NPs and cisplatin significantly inhibited on-target cisplatin resistance protein, ERCC1, via the PI3K-Akt pathway. Cisplatin 77-86 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-112 30563166-12 2018 The results suggested that enhancement of the cytotoxicity to cisplatin via administration of DMC-CHC NPs was mediated by down-regulation of the expression of TP, and ERCC1, regulated via the PI3K-Akt pathway. Cisplatin 62-71 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 167-172 30535472-8 2019 Taken together, these data suggest that miR-138-5p regulates the sensitivity of gastric cancer cells to cisplatin, possibly by modulating expression of the DNA repair proteins ERCC1 and ERCC4. Cisplatin 104-113 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 176-181 29872959-7 2018 TRF2 silencing impaired efficient DNA damage repair capacity of non-orospheric and orospheric cells and repressed ERCC1 expression levels when treated with Cisplatin. Cisplatin 156-165 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 114-119 30400270-0 2018 Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells. Cisplatin 135-144 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-43 30400270-1 2018 The 5"-3" structure-specific endonuclease ERCC1/XPF (Excision Repair Cross-Complementation Group 1/Xeroderma Pigmentosum group F) plays critical roles in the repair of cisplatin-induced DNA damage. Cisplatin 168-177 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 42-47 30400270-1 2018 The 5"-3" structure-specific endonuclease ERCC1/XPF (Excision Repair Cross-Complementation Group 1/Xeroderma Pigmentosum group F) plays critical roles in the repair of cisplatin-induced DNA damage. Cisplatin 168-177 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 53-98 30146342-0 2018 The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. Cisplatin 44-53 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 30279363-8 2018 Finally, we also showed that cells deficient in the structure-specific DNA endonuclease ERCC1-ERCC4 (ERCC1-XPF), an important mediator of cisplatin resistance, further sensitized when treated with cisplatin in the presence of gap junction forming density. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-93 30279363-8 2018 Finally, we also showed that cells deficient in the structure-specific DNA endonuclease ERCC1-ERCC4 (ERCC1-XPF), an important mediator of cisplatin resistance, further sensitized when treated with cisplatin in the presence of gap junction forming density. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 101-106 30279363-8 2018 Finally, we also showed that cells deficient in the structure-specific DNA endonuclease ERCC1-ERCC4 (ERCC1-XPF), an important mediator of cisplatin resistance, further sensitized when treated with cisplatin in the presence of gap junction forming density. Cisplatin 197-206 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-93 30279363-8 2018 Finally, we also showed that cells deficient in the structure-specific DNA endonuclease ERCC1-ERCC4 (ERCC1-XPF), an important mediator of cisplatin resistance, further sensitized when treated with cisplatin in the presence of gap junction forming density. Cisplatin 197-206 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 101-106 30066933-1 2018 The activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling and upregulation of excision repair cross complementation group 1 (ERCC1) are the two most important factors that confer resistance to cisplatin (DDP) therapy in non-small-cell lung cancer (NSCLC). Cisplatin 260-269 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 145-190 30146342-0 2018 The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. Cisplatin 108-117 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 29980176-0 2018 The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. Cisplatin 65-74 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 29980176-4 2018 This study aimed to evaluate if polymorphisms in two main genes in the NER pathway, excision repair cross-complementing group 1 and 2 (ERCC1 and ERCC2) could affect the histological response to cisplatin based chemotherapy or clinical outcomes, particularly, event free survival (EFS) and overall survival (OS) rates. Cisplatin 194-203 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 135-140 29905882-0 2018 ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. Cisplatin 55-64 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 29905882-9 2018 Our findings support the hypothesis that NS-NSCLC displaying a low ERCC1 expression might benefit from cisplatin-based chemotherapy. Cisplatin 103-112 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 67-72 29620255-9 2018 The region encompassing the overlapping genes ERCC1, CD3EAP and PPP1R13L may be involved in linking the upstream and downstream genes, while the different splicing isoforms of ERCC1 affect the expression of its overlapping genes, suggesting potential application in cisplatin resistance in NSCLC treatment. Cisplatin 266-275 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 46-51 29620255-9 2018 The region encompassing the overlapping genes ERCC1, CD3EAP and PPP1R13L may be involved in linking the upstream and downstream genes, while the different splicing isoforms of ERCC1 affect the expression of its overlapping genes, suggesting potential application in cisplatin resistance in NSCLC treatment. Cisplatin 266-275 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 176-181 29482102-1 2018 ERCC1/XPF endonuclease plays an important role in multiple DNA repair pathways and stands as a potential prognostic and predictive biomarker for cisplatin-based chemotherapy. Cisplatin 145-154 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 29177570-12 2018 CONCLUSIONS: ERCC1 polymorphism influenced the extent of CINV control in patients receiving cisplatin-based chemotherapy. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 29315773-0 2018 miR-451 selectively increases sensitivity to cisplatin in ERCC1-high non-small cell lung cancer cells. Cisplatin 45-54 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 58-63 29330293-7 2018 The LIN28B-long isoform-expressing cells demonstrated increased drug resistance to 5-fluorouracil and cisplatin through the upregulation of ERCC1, a DNA repair gene, in a LET-7-dependent manner. Cisplatin 102-111 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 140-145 29399358-9 2018 The findings suggest that ERCC1 expression could be a predictive biomarker for chemotherapy response to 5-FU/cisplatin in HNSCC. Cisplatin 109-118 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 26-31 29315773-10 2018 Furthermore, miR-451 overexpression selectively enhanced cisplatin sensitivity in ERCC1-high NSCLC cells, as evidenced by reduction of cell viability with a dose manner. Cisplatin 57-66 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 29315773-13 2018 This study demonstrates that miR-451 selectively promotes sensitivity to cisplatin in ERCC1-high NSCLC cells. Cisplatin 73-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-91 29156754-3 2017 ERCC1 is a DNA repair gene which can complex with XPF to repair cisplatin-induced DNA damage and cause chemotherapy resistance. Cisplatin 64-73 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 29578165-0 2018 Predictive value of excision repair cross-complementation group 1 protein in locoregionally advanced nasopharyngeal carcinomas receiving cisplatin-based concurrent chemoradiotherapy. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-65 29578165-1 2018 Objective: To investigate the ability of excision repair cross-complementation group 1 (ERCC1) protein to predict cisplatin-based concurrent chemoradiotherapy (CCRT) response in locoregionally advanced nasopharyngeal carcinoma (NPC). Cisplatin 114-123 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-86 29439312-3 2018 OBJECTIVE: This study aimed to investigate the clinical significance of ERCC1 expression in NPC treated with cisplatin-based concurrent chemoradiotherapy in locoregionally advanced NPC. Cisplatin 109-118 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 29439312-4 2018 METHODS: The expression level of ERCC1 and its association with clinicopathological characteristics in 205 locoregionally advanced NPC patients receiving cisplatin-based concurrent chemoradiotherapy were analyzed retrospectively. Cisplatin 154-163 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 33-38 29439312-8 2018 CONCLUSIONS: ERCC1 expression might be a useful predictive marker in patients with locoregionally advanced NPC receiving cisplatin-based concurrent chemoradiotherapy. Cisplatin 121-130 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 29578165-1 2018 Objective: To investigate the ability of excision repair cross-complementation group 1 (ERCC1) protein to predict cisplatin-based concurrent chemoradiotherapy (CCRT) response in locoregionally advanced nasopharyngeal carcinoma (NPC). Cisplatin 114-123 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-93 29578165-6 2018 The Kaplan-Meier plots revealed that the low-ERCC1 expression was significantly associated with better L-FFS, FFS, and OS of locally advanced NPC patients receiving cisplatin-based CCRT. Cisplatin 165-174 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 29578165-8 2018 Conclusion: ERCC1 expression may be a useful predictive marker in patients with locoregionally advanced NPC, who are receiving cisplatin-based CCRT. Cisplatin 127-136 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-17 29156754-5 2017 The expression of this larger ERCC1 transcript dramatically increased following cisplatin treatment in ovarian cancer cells and was regulated by the MAPK pathway. Cisplatin 80-89 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-35 28345838-1 2017 The excision repair cross-complementation 1(ERCC1) enzyme plays an essential role in the nucleotide excision repair pathway, removing platinum-induced DNAadducts and contributing to cisplatin resistance. Cisplatin 182-191 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-49 27737534-0 2017 ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. Cisplatin 64-73 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 27737534-0 2017 ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 28535002-7 2017 ERCC1 and YAP can promote cisplatin resistance in human OSCC. Cisplatin 26-35 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 28422153-5 2017 Gemcitabine/cisplatin model was based on training group of 71 patients and included CRP, histological type, performance status, RRM1 rs1042927, ERCC2 rs13181, ERCC1 rs3212986, and XRCC1 rs25487. Cisplatin 12-21 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 159-164 28659181-10 2017 CONCLUSIONS: ERCC1 expression proved to be a significant prognostic factor for survival in our metastatic or recurrent cervical cancer population treated with cisplatin based chemotherapy. Cisplatin 159-168 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 28260069-6 2017 ERCC1 expression in this cell line is high and contributes to its resistance to cisplatin. Cisplatin 80-89 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 28260069-7 2017 Suppression of ERCC1 decreased XWLC05 proliferation in vitro (IC50 of cisplatin 1.34 microM for shRNA-infected cells vs. 4.54 microM for control cells) and increased the apoptotic rate after treatment with cisplatin (81.2% shRNA cells vs. 58% control cells, P<0.05). Cisplatin 70-79 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 15-20 28260069-7 2017 Suppression of ERCC1 decreased XWLC05 proliferation in vitro (IC50 of cisplatin 1.34 microM for shRNA-infected cells vs. 4.54 microM for control cells) and increased the apoptotic rate after treatment with cisplatin (81.2% shRNA cells vs. 58% control cells, P<0.05). Cisplatin 206-215 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 15-20 26918827-1 2017 This study aimed to investigate the associations of XPC c.2815A>C, XPD c.934G>A and c.2251A>C, XPF c.2505T>C and ERCC1 c.354C>T single nucleotide polymorphisms (SNPs) of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin (CDDP) chemoradiation. Cisplatin 302-311 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 125-130 26918827-1 2017 This study aimed to investigate the associations of XPC c.2815A>C, XPD c.934G>A and c.2251A>C, XPF c.2505T>C and ERCC1 c.354C>T single nucleotide polymorphisms (SNPs) of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin (CDDP) chemoradiation. Cisplatin 313-317 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 125-130 26918827-7 2017 Our data present preliminary evidence that XPC c.2815A>C, XPD c.934G>A and c.2251A>C, and ERCC1 c.354C>T SNPs alter outcome of HNSCC patients treated with CDDP chemoradiation. Cisplatin 167-171 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 99-104 28361849-7 2017 Long-term cultivation of HT-29 cells in the presence of cisplatin and IFN resulted in 5-fold suppression of ERCC1 expression. Cisplatin 56-65 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 108-113 28345838-3 2017 We hypothesized that assigning cisplatin based on pretreatment ERCC1 expressionwould improve response and survival. Cisplatin 31-40 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 63-68 28345838-8 2017 Positive ERCC1 expressionwas associated with short PFS (median, 5 months vs. 7 months; P = 0.043), short OS (median, 9 months vs. 11 months;P = 0.033) and poor response to cisplatin based chemotherapy (P = 0.046). Cisplatin 172-181 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-14 27610644-2 2016 ERCC1 expression, evaluated by techniques such as immunohistochemistry, has been associated with clinical response; ERCC1+ tumors are more resistant to cisplatin treatment than are ERCC1- tumors. Cisplatin 152-161 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 27893326-13 2017 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). Cisplatin 58-67 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 27893326-13 2017 Median OS was 8.0 (paclitaxel and pemetrexed) versus 9.6 (cisplatin and pemetrexed) months for ERCC1-positive patients (HR, 1.11; 95% CI, 0.85 to 1.44), and 10.3 (paclitaxel and pemetrexed) versus 11.6 (cisplatin and pemetrexed) months for ERCC1-negative patients (HR, 0.99; 95% CI, 0.73 to 1.33; interaction P = .64). Cisplatin 203-212 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 27610644-2 2016 ERCC1 expression, evaluated by techniques such as immunohistochemistry, has been associated with clinical response; ERCC1+ tumors are more resistant to cisplatin treatment than are ERCC1- tumors. Cisplatin 152-161 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 27610644-2 2016 ERCC1 expression, evaluated by techniques such as immunohistochemistry, has been associated with clinical response; ERCC1+ tumors are more resistant to cisplatin treatment than are ERCC1- tumors. Cisplatin 152-161 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 27650543-0 2016 Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Cisplatin 96-105 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 27473273-9 2016 Although we found that expression knockdown of the NER-associated genes XPA and ERCC1 sensitized the three NSCLC-derived cell lines to cisplatin, the sensitization effect was more significant in Calu-1 cells than in A549 and A549/DR cells, implying that the innate cisplatin resistance in Calu-1 cells may result from an increased NER activity. Cisplatin 135-144 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 80-85 28105156-9 2016 Additionally, the differences in the gene and protein expression levels of excision repair cross-completion gene 1 (ERCC1), a gene that promotes drug resistance to cisplatin, were compared between the two groups. Cisplatin 164-173 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 75-114 28105156-9 2016 Additionally, the differences in the gene and protein expression levels of excision repair cross-completion gene 1 (ERCC1), a gene that promotes drug resistance to cisplatin, were compared between the two groups. Cisplatin 164-173 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 27650543-2 2016 ERCC1-XPF (ERCC1-ERCC4) repairs cisplatin-DNA intrastrand adducts and interstrand crosslinks and its specific inhibition has been shown to enhance cisplatin cytotoxicity in cancer cells. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 27650543-2 2016 ERCC1-XPF (ERCC1-ERCC4) repairs cisplatin-DNA intrastrand adducts and interstrand crosslinks and its specific inhibition has been shown to enhance cisplatin cytotoxicity in cancer cells. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 11-16 27650543-2 2016 ERCC1-XPF (ERCC1-ERCC4) repairs cisplatin-DNA intrastrand adducts and interstrand crosslinks and its specific inhibition has been shown to enhance cisplatin cytotoxicity in cancer cells. Cisplatin 147-156 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 27650543-2 2016 ERCC1-XPF (ERCC1-ERCC4) repairs cisplatin-DNA intrastrand adducts and interstrand crosslinks and its specific inhibition has been shown to enhance cisplatin cytotoxicity in cancer cells. Cisplatin 147-156 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 11-16 27514406-8 2016 IMPLICATIONS: This study provides a solid rationale for the stratification of lung adenocarcinoma patients according to the functional ERCC1- and mutational TP53 status, where functionally ERCC1-incompetent patients could benefit from sequential cisplatin and etoposide chemotherapy. Cisplatin 246-255 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 189-194 27514406-2 2016 Mechanisms of cisplatin resistance have been extensively investigated, and ERCC1 has emerged as a key player due to its central role in the repair of cisplatin-induced DNA lesions. Cisplatin 150-159 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 75-80 27514406-4 2016 Therefore, we employed an autochthonous mouse model of Kras-driven lung adenocarcinoma resembling human lung adenocarcinoma to investigate the role of Ercc1 in the response to cisplatin treatment. Cisplatin 176-185 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 151-156 27721259-0 2016 Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Cisplatin 125-134 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-59 27514406-6 2016 Furthermore, tumors that relapsed after cisplatin treatment in our model develop a robust etoposide sensitivity that is independent of the Ercc1 status and depends solely on previous cisplatin exposure. Cisplatin 40-49 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 139-144 27721259-1 2016 OBJECTIVE: The purpose of this study was to evaluate the expression of excision repair cross-complementation group 1 (ERCC1) in locoregionally advanced nasopharyngeal carcinoma (NPC) treated with cisplatin-based induction chemotherapy. Cisplatin 196-205 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 71-116 27721259-1 2016 OBJECTIVE: The purpose of this study was to evaluate the expression of excision repair cross-complementation group 1 (ERCC1) in locoregionally advanced nasopharyngeal carcinoma (NPC) treated with cisplatin-based induction chemotherapy. Cisplatin 196-205 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 118-123 27721259-9 2016 CONCLUSION: Cisplatin-induced short-term ORR was decreased in nasopharyngeal carcinoma patients with high ERCC1 expression, which increased the risk of metastasis. Cisplatin 12-21 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 106-111 27501338-2 2016 Addition of cisplatin (Cis) to Gem has resulted in increased PFS for advanced and metastatic disease, which may be predicted by low expression of excision repair cross-complementing group-1 (ERCC1), the key enzyme in nucleotide excision repair. Cisplatin 12-21 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 146-189 27501338-2 2016 Addition of cisplatin (Cis) to Gem has resulted in increased PFS for advanced and metastatic disease, which may be predicted by low expression of excision repair cross-complementing group-1 (ERCC1), the key enzyme in nucleotide excision repair. Cisplatin 12-21 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 191-196 27453264-9 2016 Furthermore, the application of Cisplatin also altered the expression level of tumor related proteins, such as ERCC1, Ki67, and CDK6. Cisplatin 32-41 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 111-116 26870207-9 2016 The expression of ERCC1 and BRCA1 was significantly associated with the DFS time in patients with NSCLC treated with adjuvant cisplatin-based chemotherapy, respectively. Cisplatin 126-135 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 26870207-2 2016 It was hypothesized in the present study that the protein levels of excision repair cross-complementation group 1 (ERCC1), breast cancer 1 (BRCA1), ribonucleotide reductase M1 (RRM1) and class III beta-tubulin (TUBB3) may influence the therapeutic effect of adjuvant cisplatin-based chemotherapy. Cisplatin 267-276 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 115-120 26870207-8 2016 In addition, patients lacking the expression of ERCC1 and BRCA1 benefited more from adjuvant cisplatin-based chemotherapy compared with patients that expressed either ERCC1 or BRCA1 (HR, 3.102; 95% CI, 1.343-7.163; P=0.008). Cisplatin 93-102 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 48-53 26870207-10 2016 The combination of the ERCC1 and BRCA1 expression levels may be a promising prognostic prediction for adjuvant cisplatin-based chemotherapy. Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 23-28 26384430-0 2015 CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene. Cisplatin 44-53 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 121-126 26384430-7 2015 These results demonstrate that CITED2/p300 can be recruited by p53 at the promoter of the repair gene ERCC1 in response to cisplatin-induced DNA damage. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 102-107 26384430-8 2015 The CITED2/p300/p53/ERCC1 pathway is thus involved in the cell response to cisplatin and represents a potential target for cancer therapy. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 26345951-1 2015 We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. Cisplatin 86-95 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 51-56 26882613-1 2015 OBJECTIVE: To explore the effect of peimine on excision repair cross-complementation 1 (ERCC1) mRNA and lung resistant protein (LRP) expressions in A549/cisplatin (DDP) multidrug resistance (MDR) cell line. Cisplatin 153-162 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-93 26313152-8 2015 Expression of anti-apoptotic proteins Bcl-2 and Mcl-1 and DNA repair associated molecules ATM, CHK1, TP73, p53, and ERCC1 were significantly up regulated in cisplatin-treated A549sc and H157sc cells, but no increase was detected in A549IL-6si and H157IL-6si cells. Cisplatin 157-166 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 26400354-1 2015 We assessed the role of single nucleotide polymorphisms (SNPs) in ERCC1 and ERCC2 genes in the clinical outcomes for osteosarcoma patients receiving cisplatin-based treatment. Cisplatin 149-158 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 26400354-6 2015 In conclusion, our results suggest that the ERCC1 rs11615 polymorphism might influence the response to cisplatin-based chemotherapy and affect the clinical outcome for osteosarcoma patients. Cisplatin 103-112 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-49 26162296-5 2015 Further, ERCC1 mRNA expression and in vitro sensitivity to cisplatin were correlated in 25 bladder urothelial carcinoma cell lines. Cisplatin 59-68 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-14 25946469-2 2015 The authors hypothesized that the ERCC1 genotype for the SNPs cytosine-to-thymine substitution at codon 118 (C118T) and cytosine-to-adenine substitution at codon 8092 (C8092A) is prognostic in patients with nasopharyngeal carcinoma (NPC) who receive either radiotherapy (RT) or cisplatin plus RT. Cisplatin 278-287 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 34-39 25944617-0 2015 The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Cisplatin 73-82 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 26165688-13 2015 CONCLUSIONS: ERCC1 expression could be a predictive and prognostic factor in LACSCC patients who receive cisplatin monotherapy. Cisplatin 105-114 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 25944617-6 2015 ERCC1 knockdown increased the cisplatin sensitivity of NSCLC cell lines with high ERCC1 expression without GOF p53 mutations. Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 25944617-6 2015 ERCC1 knockdown increased the cisplatin sensitivity of NSCLC cell lines with high ERCC1 expression without GOF p53 mutations. Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 25944617-7 2015 In addition, in low ERCC1 expression NSCLC cell lines, knockdown of GOF mutant p53 enhanced cisplatin sensitivity. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 25944617-8 2015 Further double knockdown of ERCC1 and GOF mutant p53 but not ERCC1 knockdown alone increased the cisplatin sensitivity of cells with both high ERCC1 expression and GOF p53 mutations. Cisplatin 97-106 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 28-33 25944617-9 2015 Therefore, this study demonstrated that ERCC1 expression combined with p53 mutation status may determine the efficacy of cisplatin and HDACi combined therapy and guide the development of future NSCLC therapies. Cisplatin 121-130 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 40-45 25941922-0 2015 Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. Cisplatin 60-69 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 26200905-1 2015 Preclinical and clinical studies have suggested that expression of ribonucleotide reductase regulatory subunit M1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) is associated with resistance to gemcitabine and cisplatin, respectively. Cisplatin 228-237 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 172-177 25941922-0 2015 Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. Cisplatin 84-93 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 25956741-7 2015 We demonstrate that two of these compounds display specificity in vitro for ERCC1-XPF over two other endonucleases, bind to ERCC1-XPF, inhibit Nucleotide Excision Repair in two independent assays and specifically sensitise Nucleotide Excision Repair-proficient, but not Nucleotide Excision Repair-deficient human and mouse cells to cisplatin. Cisplatin 332-341 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 76-81 25941922-1 2015 The aim of the study was to investigate the potential mechanisms that interferencing of excision repair cross-complementing gene 1 (ERCC1) mediated by lentiviral vector in cisplatin-resistant ovarian cancer SKOV3/DDP cells. Cisplatin 172-181 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 88-130 25941922-1 2015 The aim of the study was to investigate the potential mechanisms that interferencing of excision repair cross-complementing gene 1 (ERCC1) mediated by lentiviral vector in cisplatin-resistant ovarian cancer SKOV3/DDP cells. Cisplatin 172-181 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 132-137 25941922-7 2015 The results of cell viability assay demonstrated that interference with ERCC1 gene increased the sensitivity of SKOV3/DDP cells to cisplatin (p<0.01). Cisplatin 131-140 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 25941922-11 2015 ERCC1 gene silencing effectively reversed SKOV3/DDP cell resistance to cisplatin and increased sensitivity to cisplatin resistance in cisplatin-resistant ovarian cancer cells. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 25941922-11 2015 ERCC1 gene silencing effectively reversed SKOV3/DDP cell resistance to cisplatin and increased sensitivity to cisplatin resistance in cisplatin-resistant ovarian cancer cells. Cisplatin 110-119 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 25941922-11 2015 ERCC1 gene silencing effectively reversed SKOV3/DDP cell resistance to cisplatin and increased sensitivity to cisplatin resistance in cisplatin-resistant ovarian cancer cells. Cisplatin 110-119 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 25941922-13 2015 Thus, ERCC1 could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer and it would provide new ideas for epigenetic therapy of drug-resistant epithelial ovarian cancer. Cisplatin 71-80 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 6-11 26905109-0 2015 Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy? Cisplatin 173-182 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-69 26905109-2 2015 The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin-based chemotherapy according to excision repair cross-complementation 1 (ERCC1) expression. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 159-198 26905109-2 2015 The purpose of this study was to evaluate the response to treatment and survival in patients with NSCLC treated with cisplatin-based chemotherapy according to excision repair cross-complementation 1 (ERCC1) expression. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 200-205 25434755-1 2015 This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of non-small cell lung cancer (NSCLC) cells. Cisplatin 158-167 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 57-101 25857670-1 2015 Our aim of the study was to investigate the precise relationship of repair cross-complementation group 1 (ERCC1) expression and the survival as well as objective response rate to cisplatin-based concurrent chemoradiotherapy (CCRT) and a meta-analysis was conducted to analysis ERCC1"s prognostic roles in head and neck cancer. Cisplatin 179-188 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 106-111 25857670-1 2015 Our aim of the study was to investigate the precise relationship of repair cross-complementation group 1 (ERCC1) expression and the survival as well as objective response rate to cisplatin-based concurrent chemoradiotherapy (CCRT) and a meta-analysis was conducted to analysis ERCC1"s prognostic roles in head and neck cancer. Cisplatin 179-188 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 277-282 25857670-6 2015 Low/negative expression of ERCC1 was associated with longer overall survival (OS) and profession-free survival (PFS) after receiving cisplatin-based CCRT therapy (HR 0.38; 95% confidence interval (CI) 0.21-0.63; P<0.001 and HR 0.37; 95%CI 0.21-0.63; P<0.001). Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 25857670-9 2015 The conclusion is that ERCC1 might be the one of adverse prognostic factors affecting the survival time and objective response to cisplatin-based chemoradiotherap due to its drug-resistance characteristics. Cisplatin 130-139 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 23-28 26125934-0 2015 Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer. Cisplatin 96-105 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 26-31 26125934-1 2015 The aim of this study was to define the genotypes of UGT1A1 and ERCC1 and to examine their relationship with the efficacy and toxicity of a combination therapy of irinotecan and cisplatin in patients with advanced ovarian cancer. Cisplatin 178-187 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 64-69 26125934-8 2015 Furthermore, the results suggest that ERCC1 WW carriers might obtain a better rate of clinical response from a combined irinotecan and cisplatin regimen than ERCC1 WM+MM carriers. Cisplatin 135-144 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-43 26137163-3 2015 Excision repair cross complementation 1 gene (ERCC1) is involved in the repair of DNA damage caused by cisplatin, and ribonucleotide reductase M1 subunit (RRM1) is associated with gemcitabine resistance in tumor cells. Cisplatin 103-112 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 46-51 26137163-4 2015 The current study reports the case of a patient with advanced squamous cell lung carcinoma exhibiting low ERCC1 and RRM1 expression levels, who experienced long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy. Cisplatin 223-232 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 106-111 26045829-6 2015 In conclusion, our study found that ERCC1 rs11615 polymorphism can influence the chemotherapy response and overall survival of NSCLC patients receiving cisplatin-based chemotherapy. Cisplatin 152-161 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-41 25434755-1 2015 This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of non-small cell lung cancer (NSCLC) cells. Cisplatin 158-167 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 103-108 25434755-10 2015 In the present study, the results demonstrated that ERCC1 had no effect on cell proliferation, cell cycle and the ability of invasion, but showed significant impact on cisplatin response of the NSCLC H1299 cells. Cisplatin 168-177 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 52-57 25434755-11 2015 Furthermore, siRNA-induced suppression of ERCC1 evidently enhanced sensitivity to cisplatin of NSCLC A549 cells. Cisplatin 82-91 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 42-47 26557761-1 2015 BACKGROUND: We aimed to investigate the impact of RRM1 and ERCC1 expression on response to cisplatin and/or gemcitabine chemotherapy in patients with lung, ovarian or pancreatic cancer. Cisplatin 91-100 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 25650716-12 2015 Both EGR1 and MIR152 expression levels were significantly lower in ovarian cancer tissues with high levels of ERCC1 (excision repair cross-complementation group 1), a marker for cisplatin-resistance. Cisplatin 178-187 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 110-115 25989663-0 2015 [Correlation between expression of ERCC1 and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma]. Cisplatin 62-71 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 25989663-1 2015 OBJECTIVE: To study the expression of excision repair cross-complementing 1 (ERCC1) and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma (NPC). Cisplatin 105-114 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 38-75 25989663-1 2015 OBJECTIVE: To study the expression of excision repair cross-complementing 1 (ERCC1) and the treatment of cisplatin-based chemotherapy in local advanced nasopharyngeal carcinoma (NPC). Cisplatin 105-114 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 77-82 25217323-1 2014 Excision repair cross-complementing gene 1 (ERCC1) protein is proposed as a predictor for cisplatin efficacy in patients with non-small cell lung cancer (NSCLC). Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-42 26557761-0 2015 ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine. Cisplatin 106-115 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 26066774-0 2015 Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation. Cisplatin 120-129 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 19-24 26066774-2 2015 In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Cisplatin 162-171 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 82-87 25217323-1 2014 Excision repair cross-complementing gene 1 (ERCC1) protein is proposed as a predictor for cisplatin efficacy in patients with non-small cell lung cancer (NSCLC). Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-49 25217323-3 2014 The purpose of this study is to assess whether ERCC1 expression level is linked to cisplatin sensitivity and clinical outcomes in resected NSCLC patients. Cisplatin 83-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 25217323-6 2014 The association between ERCC1 expression and cisplatin sensitivity was tested by Spearman"s rho test. Cisplatin 45-54 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 25217323-11 2014 ERCC1 expression was significantly correlated with the sensitivity of cisplatin in vitro (p < 0.01, r = 0.37). Cisplatin 70-79 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 25191856-4 2014 Evidence suggests polymorphisms in genes encoding excision repair cross-complementing group 1 (ERCC1), a protein involved in nuclear excision repair (NER), may help predict response to cisplatin and other platinum-based chemotherapeutics. Cisplatin 185-194 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-93 25191856-4 2014 Evidence suggests polymorphisms in genes encoding excision repair cross-complementing group 1 (ERCC1), a protein involved in nuclear excision repair (NER), may help predict response to cisplatin and other platinum-based chemotherapeutics. Cisplatin 185-194 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 95-100 25083297-0 2014 Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. Cisplatin 136-145 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 44-78 25083297-0 2014 Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy. Cisplatin 136-145 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 80-85 25083297-4 2014 Excision repair cross complement-1 (ERCC1) overexpression has been correlated with poorer response to cisplatin based chemotherapy. Cisplatin 102-111 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-34 25083297-4 2014 Excision repair cross complement-1 (ERCC1) overexpression has been correlated with poorer response to cisplatin based chemotherapy. Cisplatin 102-111 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-41 25083297-5 2014 We examined the expression of BCRP and ERCC1 in patients with esophageal cancer and correlated it with survival in patients receiving irinotecan and cisplatin based chemotherapy. Cisplatin 149-158 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-44 24935625-3 2014 The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. Cisplatin 205-214 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 102-147 24817012-9 2014 In CDDP-treated cells, ERCC1 mRNA and protein expression increased. Cisplatin 3-7 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 23-28 24935625-3 2014 The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementation group-1 (ERCC1) in locally advanced NSCLC patients that received cisplatin-based chemotherapy. Cisplatin 205-214 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 149-154 24935625-11 2014 It was found that ERCC1 protein expression might play an important role in the prognosis of locally advanced NSCLC patients treated with cisplatin-based adjuvant chemotherapy. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 18-23 24699918-0 2014 ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Cisplatin 43-52 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 24699918-1 2014 The present study examined the effects of cisplatin (DDP) on gastric carcinoma cells by inhibiting the expression of excision repair cross-complementing 1 (ERCC1) using RNA interference (RNAi). Cisplatin 42-51 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 117-154 24699918-1 2014 The present study examined the effects of cisplatin (DDP) on gastric carcinoma cells by inhibiting the expression of excision repair cross-complementing 1 (ERCC1) using RNA interference (RNAi). Cisplatin 42-51 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 156-161 24799992-13 2014 In the combination treatment, melatonin reversed the effects of cisplatin by suppressing the over-expression of mTOR and ERCC 1 and enhancing the expression levels of Beclin-1 and microtubule-associated protein-light chain3-II, leading to intracellular autophagosome progression. Cisplatin 64-73 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 121-127 25076246-2 2014 We conducted this study to assess the value of excision repair cross-complementation group 1 (ERCC1) protein expression in predicting the clinical outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy. Cisplatin 233-242 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-92 25076246-2 2014 We conducted this study to assess the value of excision repair cross-complementation group 1 (ERCC1) protein expression in predicting the clinical outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy. Cisplatin 233-242 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 94-99 25076246-10 2014 CONCLUSIONS: Low ERCC1 expression is associated with prolonged survival in patients with locally advanced nasopharyngeal cancer receiving cisplatin-based concurrent chemoradiotherapy. Cisplatin 138-147 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 17-22 24799992-0 2014 Melatonin attenuates cisplatin-induced HepG2 cell death via the regulation of mTOR and ERCC1 expressions. Cisplatin 21-30 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 87-92 24158589-11 2014 Overall, this study explores the link between the ERCC1 deleterious variants and cisplatin chemotherapy for various cancers with the help of molecular docking and molecular dynamic approaches. Cisplatin 81-90 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 50-55 24638013-2 2014 Excision repair cross-complementation group 1 (ERCC1) was shown to predict cisplatin-based chemotherapy response; EGFR mutations were predictive of epidermal growth factor receptor inhibition response. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-45 24638013-2 2014 Excision repair cross-complementation group 1 (ERCC1) was shown to predict cisplatin-based chemotherapy response; EGFR mutations were predictive of epidermal growth factor receptor inhibition response. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 47-52 24403499-3 2014 The combination of gemcitabine and cisplatin is based on gemcitabine-induced increased formation and retention of DNA-platinum adducts, which can be explained by a decrease of excision repair cross-complementing group-1 (ERCC1)-mediated DNA repair. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 176-219 24403499-3 2014 The combination of gemcitabine and cisplatin is based on gemcitabine-induced increased formation and retention of DNA-platinum adducts, which can be explained by a decrease of excision repair cross-complementing group-1 (ERCC1)-mediated DNA repair. Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 221-226 24403494-0 2014 ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. Cisplatin 72-81 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 24088734-2 2013 Elevated activity of DNA repair mechanisms, such as the nucleotide excision repair (NER) pathway, of which ERCC1 is a rate-limiting element, are associated with cisplatin and possibly RT resistance. Cisplatin 161-170 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-112 24403450-1 2014 UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. Cisplatin 221-230 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-131 24403450-1 2014 UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. Cisplatin 221-230 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 133-138 24403450-1 2014 UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. Cisplatin 276-285 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-131 24403450-1 2014 UNLABELLED: BACKGROUD/AIM: We previously demonstrated that high protein expression of excision repair cross-complementation group-1 (ERCC1) was associated with poor disease-free survival in patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, and was shown to be an independent prognostic factor. Cisplatin 276-285 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 133-138 24403450-2 2014 In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU). Cisplatin 159-168 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 35-40 24403450-6 2014 ERCC1 mRNA expression levels were investigated using quantitative RT-PCR following treatment with cisplatin with and without 5-FU. Cisplatin 98-107 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 24403450-9 2014 ERCC1 expression was significantly elevated by cisplatin treatment, which was reduced by co-administration of 5-FU in HCA-1, TCO-2 and HCA-1R cells. Cisplatin 47-56 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 24403450-10 2014 CONCLUSION: The current study demonstrated an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. Cisplatin 102-111 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 24403450-11 2014 Co-administration of cisplatin and 5-FU revealed synergistic or additive effects through inhibition of ERCC1 expression in cervical adenocarcinoma cells. Cisplatin 21-30 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 103-108 24403450-12 2014 Therefore, it is possible that a combination therapy of cisplatin and 5-FU or 5-FU derivatives constitutes an ideal treatment regimen, from the ERCC1 inhibition point of view in cervical adenocarcinoma. Cisplatin 56-65 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 144-149 24083589-12 2013 CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. Cisplatin 195-204 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 23962907-0 2013 ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. Cisplatin 104-113 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 24045016-5 2013 Combination chemotherapy was selected based on ERCC1 and RRM1 SNPs: we assume that patients with one or two C alleles at position 118 and with one or two A alleles at position 8092 in ERCC1 gene would correspond to Cisplatin non-responder and than with two A alleles at -37 and two C alleles at -524 in RRM1 gene to gemcitabine non-responder. Cisplatin 215-224 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 184-189 23962907-4 2013 RESULTS: We found that the ERCC1 rs3212986, although not associated with therapeutic response, is an independent predictive marker of better outcome in a cisplatin/5-FU-based neoadjuvant setting (hazard ratio: 0.38, 95% confidence interval: 0.2-0.73, P=0.008). Cisplatin 154-163 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 23962907-6 2013 CONCLUSION: Our study indicates the ERCC1 rs3212986 as a predictive marker in the cisplatin/5-FU-based neoadjuvant setting, and also suggests its use as a marker to select the appropriate therapeutic approach in esophageal cancer patients. Cisplatin 82-91 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 36-41 23817665-7 2013 In the cisplatin-resistant ovarian carcinoma cells, beta-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. Cisplatin 7-16 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-152 23773262-8 2013 A 3-fold increase in IC50 of cisplatin in cell lines with high 19q13-ERCC1 CN compared with cells without CNV was shown. Cisplatin 29-38 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 69-74 24064970-4 2013 The ERCC1-XPF nuclease is critical to DNA repair pathways resolving cisplatin-induced lesions. Cisplatin 68-77 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 4-9 24064970-13 2013 CONCLUSION: ERCC1-XPF protein expression by the specific FL297 and 4F9 antibodies is prognostic in patients undergoing definitive cisplatin-radiotherapy for HNSCC, irrespective of HPV status. Cisplatin 130-139 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-17 23817665-7 2013 In the cisplatin-resistant ovarian carcinoma cells, beta-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. Cisplatin 7-16 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 154-160 23817665-7 2013 In the cisplatin-resistant ovarian carcinoma cells, beta-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-152 23817665-7 2013 In the cisplatin-resistant ovarian carcinoma cells, beta-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 154-160 23817665-7 2013 In the cisplatin-resistant ovarian carcinoma cells, beta-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 107-152 23817665-7 2013 In the cisplatin-resistant ovarian carcinoma cells, beta-elemene abrogated cisplatin-induced expression of excision repair cross-complementation group-1 (ERCC-1), a marker gene in the nucleotide excision repair pathway that repairs cisplatin-caused DNA damage. Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 154-160 23975218-7 2013 The markers ERCC-1, XAF and anti-apoptotic proteins of the Bcl-2 family seem to represent the most promising biomarkers associated with response to adjuvant cisplatin-based chemotherapy. Cisplatin 157-166 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-18 23712330-0 2013 Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cisplatin 126-135 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 17-22 23712330-4 2013 RESULTS: The ERCC1 C8092A polymorphism was an independent predictor of PFS in Chinese NPC patients treated with cisplatin-based chemotherapy. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 13-18 23712330-7 2013 CONCLUSION: The ERCC1 C8092A polymorphism might be a useful predictive marker in metastatic/recurrent NPC patients treated with cisplatin-based chemotherapy. Cisplatin 128-137 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 16-21 23807173-12 2013 CONCLUSIONS: High levels of ERCC1 were associated with non-CPS, suggesting that ERCC1 could be used as a potential indicator of the response to cisplatin and prognosis in ns-TGCTs. Cisplatin 144-153 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 28-33 23807173-0 2013 Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Cisplatin 83-92 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 23807173-12 2013 CONCLUSIONS: High levels of ERCC1 were associated with non-CPS, suggesting that ERCC1 could be used as a potential indicator of the response to cisplatin and prognosis in ns-TGCTs. Cisplatin 144-153 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 80-85 23807173-7 2013 RESULTS: High ERCC1 expression was observed in the non-CPS cells, and both ERCC1 and gammaH2AX expressions were augmented after cisplatin treatment. Cisplatin 128-137 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 75-80 23645290-0 2013 ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cisplatin 77-86 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 23645290-13 2013 CONCLUSION: Excision repair cross-complementing gene 1 by IHC might predict patients more likely to benefit from adjuvant cisplatin-based chemotherapy in curatively resected gastric cancer. Cisplatin 122-131 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-54 23580445-6 2013 In particular, the compound labeled NSC 130813 [4-[(6-chloro-2-methoxy-9-acridinyl)amino]-2-[(4-methyl-1-piperazinyl)methyl]] was shown to act synergistically with cisplatin and mitomycin C; to increase UVC-mediated cytotoxicity; to modify DNA repair as indicated by the staining of phosphorylated H2AX; and to disrupt interaction between ERCC1 and XPF in cells. Cisplatin 164-173 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 339-344 23523421-0 2013 Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin. Cisplatin 123-132 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 25-30 23523421-11 2013 Protein expressions of TS and ERCC1 were associated with clinical outcomes in patients with pulmonary adenocarcinoma who were treated with pemetrexed/cisplatin as first-line chemotherapy. Cisplatin 150-159 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-35 23759026-2 2013 The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementing group-1 (ERCC1) in resected p-stage III/N2 NSCLC patients that received cisplatin-based adjuvant chemotherapy. Cisplatin 210-219 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 102-145 23759026-2 2013 The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementing group-1 (ERCC1) in resected p-stage III/N2 NSCLC patients that received cisplatin-based adjuvant chemotherapy. Cisplatin 210-219 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 147-152 23759026-9 2013 However, it was not entirely clear whether adjuvant chemotherapy with cisplatin-based agents was beneficial for ERCC1-negative patients with p-stage III/N2. Cisplatin 70-79 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 112-117 23759026-13 2013 In addition, it was found that ERCC1 protein expression might play an important role in the prognosis of p-stage III/N2 NSCLC patients treated with cisplatin-based adjuvant chemotherapy. Cisplatin 148-157 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 31-36 25806229-5 2013 Among them, high levels of expression of ERCC1, both at protein and mRNA levels, have been associated with resistance to cisplatin in NSCLC. Cisplatin 121-130 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 41-46 23514287-1 2013 BACKGROUND: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC). Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 16-61 23549037-0 2013 ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Cisplatin 125-134 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 23275151-0 2013 PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Cisplatin 53-62 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 23275151-6 2013 Moreover, small interfering RNA knockdown of ERCC1 in A549 and H157 cells increased their sensitivities to both cisplatin and olaparib in a synergistic manner in our model. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 45-50 23275151-7 2013 Furthermore, mechanistic studies indicated that combined PARP inhibitor and cisplatin could lead to sustained DNA double-strand breaks, prolonged G2/M cell cycle arrest with distinct activation of checkpoint kinase 1 signaling and more pronounced apoptosis preferentially in lung cancer cells with low ERCC1 expression. Cisplatin 76-85 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 302-307 23514287-1 2013 BACKGROUND: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC). Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 63-68 23514287-3 2013 METHODS: We used the 8F1 antibody to measure the level of expression of ERCC1 protein by means of immunohistochemical analysis in a validation set of samples obtained from 494 patients in two independent phase 3 trials (the National Cancer Institute of Canada Clinical Trials Group JBR.10 and the Cancer and Leukemia Group B 9633 trial from the Lung Adjuvant Cisplatin Evaluation Biology project). Cisplatin 359-368 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 22344449-4 2012 Excision repair cross complementation group 1 (ERCC1) is an enzyme that removes cisplatin-induced DNA adducts and has been related with prognosis and cisplatin response. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-57 23263828-14 2013 Our study indicates that the expression of ERCC1 evaluated by immunohistochemistry is a promising predictive marker for response in patients with metastatic ESCC receiving cisplatin-paclitaxel regimen. Cisplatin 172-181 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 43-48 23790173-7 2013 Patients with low mRNA expression of ERCC1 or TYMS preferred higher DCR to cisplatin and pemetrexed than those with high expression (P = 0.39 and P= 0.11). Cisplatin 75-84 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 37-42 23259415-0 2012 ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Cisplatin 46-55 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 23259415-1 2012 BACKGROUND: The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) who underwent cisplatin-based concurrent chemoradiotherapy (CCCRT). Cisplatin 262-271 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 69-114 23259415-1 2012 BACKGROUND: The purpose of this study was to investigate whether the excision repair cross-complementation group 1 (ERCC1) mRNA expression could predict treatment response of patients with locally advanced cervical squamous cell carcinoma (LACSCC) who underwent cisplatin-based concurrent chemoradiotherapy (CCCRT). Cisplatin 262-271 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 23171216-2 2012 ERCC1 is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy. Cisplatin 65-74 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 23171216-3 2012 High ERCC1 expression is linked to drug resistance on cisplatin-based chemotherapy. Cisplatin 54-63 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 5-10 22960937-15 2012 CONCLUSION: Combined negative ERCC1 and class III beta-tubulin immunostaining is associated with significantly prolonged PFS and OS in MPM patients receiving cisplatin-vinorelbine therapy. Cisplatin 158-167 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-35 22266871-0 2012 Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Cisplatin 70-79 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 104-109 22266871-3 2012 We therefore studied the possible relationships between Gli1, c-jun, and the upregulation of ERCC1, XPD and XRCC1 in cisplatin-resistant human ovarian cancer cells. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 93-98 22266871-8 2012 Use of the anti-Gli1 shRNA in cisplatin-resistant cells resulted in a block of the cell"s ability to upregulate genes in response to cisplatin treatment, including: c-jun, ERCC1, XPD and XRCC1. Cisplatin 30-39 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 172-177 22266871-8 2012 Use of the anti-Gli1 shRNA in cisplatin-resistant cells resulted in a block of the cell"s ability to upregulate genes in response to cisplatin treatment, including: c-jun, ERCC1, XPD and XRCC1. Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 172-177 22571922-0 2012 Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 14-19 22571922-1 2012 The aim of the present study was to evaluate the correlation between excision repair cross-complementation group 1 (ERCC1) protein with the clinical outcome of nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based induction chemotherapy. Cisplatin 213-222 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 69-114 22571922-1 2012 The aim of the present study was to evaluate the correlation between excision repair cross-complementation group 1 (ERCC1) protein with the clinical outcome of nasopharyngeal carcinoma (NPC) patients treated with cisplatin-based induction chemotherapy. Cisplatin 213-222 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 116-121 22571922-8 2012 High tumor ERCC1 expression predicts low chemotherapy response and poor survival mainly caused by more metastasis in locoregionally advanced NPC treated with cisplatin-based induction chemotherapy. Cisplatin 158-167 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 11-16 22836058-1 2013 PURPOSE: ERCC1 (excision repair cross-complementation group 1) expression has been shown to be a molecular marker of cisplatin resistance in many tumor sites, but has not been well studied in cervical cancer patients. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 9-14 23426424-6 2013 The results demonstrated that the expression levels of ERCC1 mRNA were correlated with the chemosensitivity of platinum agents, and depletion of ERCC1 sensitized the relatively resistant MKN45 cells to cisplatin and oxaliplatin. Cisplatin 202-211 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 145-150 23426424-9 2013 These results suggest that overexpression of ERCC1 is correlated with platinum drug resistance in gastric cancer cells, and that depletion of ERCC1 sensitizes gastric cancer cell lines to cisplatin and oxaliplatin. Cisplatin 188-197 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 142-147 23856142-14 2013 CONCLUSION: Targeting to inhibit antiapoptotic mitochondrial gene Bcl-2 expression in A549 cells specifically decreased the mRNA of ERCC1, TYMS, and TOP2alpha genes, and significantly increased the sensitivities of A549 cells to chemotherapeutic agents such as etoposide, cisplatin, paclitaxel and navelbine. Cisplatin 272-281 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 132-137 23299493-6 2013 Cisplatin alone induced mRNA expression of excision repair cross complementation 1 (ERCC1) and thymidine phosphorylase (TP) through phosphorylation of ERK, p38 and PI3K/AKT pathways. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 84-89 23299493-7 2013 However, fucoxanthin pretreatment significantly attenuated cisplatin-induced ERCC1 and TP mRNA expression, leading to improvement of chemotherapeutic efficacy of cisplatin. Cisplatin 59-68 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 77-82 22269178-3 2012 The International Adjuvant Lung Trial (IALT)-Bio study previously suggested ERCC1 and MSH2 as predictive of cisplatin-based therapeutic benefit. Cisplatin 108-117 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 76-81 22266184-0 2012 Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer. Cisplatin 45-54 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 73-78 22344449-4 2012 Excision repair cross complementation group 1 (ERCC1) is an enzyme that removes cisplatin-induced DNA adducts and has been related with prognosis and cisplatin response. Cisplatin 92-101 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 22344449-4 2012 Excision repair cross complementation group 1 (ERCC1) is an enzyme that removes cisplatin-induced DNA adducts and has been related with prognosis and cisplatin response. Cisplatin 174-183 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-57 22344449-4 2012 Excision repair cross complementation group 1 (ERCC1) is an enzyme that removes cisplatin-induced DNA adducts and has been related with prognosis and cisplatin response. Cisplatin 174-183 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 22344449-11 2012 In summary, our results suggest the use of ERCC1 immunohistochemistry and TOP I mRNA analysis to predict cisplatin response and prognosis in SCLC patients. Cisplatin 129-138 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 55-60 22425915-0 2012 ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. Cisplatin 111-120 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 22616552-5 2012 ERCC1 expression was analyzed in 57 patients treated with adjuvant gemcitabine plus cisplatin chemotherapy and 36 who were not treated. Cisplatin 84-93 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 22616552-9 2012 CONCLUSIONS: Among patients with completely resected transitional cell carcinoma of the bladder, those with ERCC1-negative tumors seemed to benefit more from adjuvant gemcitabine plus cisplatin chemotherapy than those with ERCC1-positive tumors. Cisplatin 184-193 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 108-113 21996734-0 2012 Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance. Cisplatin 0-9 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 94-99 21996734-5 2012 The DNA repair proteins ERCC1 and XPF are needed to remove cisplatin-induced DNA damage and we have investigated the response of these proteins to cisplatin in melanoma. Cisplatin 59-68 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 21996734-5 2012 The DNA repair proteins ERCC1 and XPF are needed to remove cisplatin-induced DNA damage and we have investigated the response of these proteins to cisplatin in melanoma. Cisplatin 147-156 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 21996734-8 2012 DUSP6 overexpression prevented cisplatin induction of both ERCC1 and XPF, resulting in increased sensitivity to cisplatin. Cisplatin 31-40 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 21996734-8 2012 DUSP6 overexpression prevented cisplatin induction of both ERCC1 and XPF, resulting in increased sensitivity to cisplatin. Cisplatin 112-121 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 21996734-9 2012 A novel ERCC1 mRNA was found that initiated upstream of the normal transcription initiation site, and was strongly regulated by both cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study. Cisplatin 133-142 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 8-13 21996734-9 2012 A novel ERCC1 mRNA was found that initiated upstream of the normal transcription initiation site, and was strongly regulated by both cisplatin and the MAPK pathway and its role in cisplatin resistance merits further study. Cisplatin 180-189 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 8-13 21996734-10 2012 The cisplatin induction of ERCC1 and XPF provides important insights into the resistance of melanoma to DNA-damaging chemotherapeutics, which is one of the major obstacles to melanoma treatment. Cisplatin 4-13 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 22284908-1 2012 BACKGROUND: The nucleotide excision repair pathway is crucial for cellular DNA integrity and the ERCC1 helicase is also potentially involved in resistance to platinum-based chemotherapy, and high levels of ERCC1 mRNA in tumours have been associated with cisplatin resistance in different human cancers. Cisplatin 254-263 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 206-211 22199271-0 2011 ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Cisplatin 78-87 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 23098477-2 2012 In the current study, we investigated the relationship of SNPs in ERCC1 and ERCC2 to cisplatin response and survival in osteosarcoma patients. Cisplatin 85-94 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 23098477-8 2012 CONCLUSION: We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin. Cisplatin 311-320 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 55-60 23098477-8 2012 CONCLUSION: We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin. Cisplatin 311-320 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 23098477-8 2012 CONCLUSION: We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin. Cisplatin 311-320 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 72-77 22031231-0 2012 Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. Cisplatin 69-78 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 4-9 22031231-1 2012 INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. Cisplatin 185-194 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 39-84 22031231-1 2012 INTRODUCTION: The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. Cisplatin 185-194 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 86-91 22031231-13 2012 CONCLUSION: Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation. Cisplatin 65-74 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 105-110 23102199-4 2012 ERCC1 is involved in removal of platinum adducts and might be a potential predictive and prognostic marker in NSCLC (non-small-cell lung cancer) treated with a cisplatin-based regimen. Cisplatin 160-169 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 21553054-3 2012 ERCC1 has also been shown to be a promising biomarker in NSCLC treated with a cisplatin-based regimen. Cisplatin 78-87 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 0-5 23147544-0 2012 RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin. Cisplatin 180-189 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 12-17 23147544-1 2012 BACKGROUND: The purpose of this study was to test the hypothesis that the immunohistochemical expression of ERCC1 and RASSF1A would predict both response to and survival after docetaxel and cisplatin combination chemotherapy in inoperable or recurrent head and neck squamous cell carcinoma. Cisplatin 190-199 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 108-113 22284908-1 2012 BACKGROUND: The nucleotide excision repair pathway is crucial for cellular DNA integrity and the ERCC1 helicase is also potentially involved in resistance to platinum-based chemotherapy, and high levels of ERCC1 mRNA in tumours have been associated with cisplatin resistance in different human cancers. Cisplatin 254-263 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 97-102 22159227-0 2012 Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Cisplatin 87-96 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 27-32 22102173-0 2012 A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. Cisplatin 46-55 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 24-29 22102173-1 2012 PURPOSE: To investigate the association between a single-nucleotide polymorphism (SNP) of ERCC1, Asn118Asn (C T), and the response of patients with late-stage non-small cell lung cancer (NSCLC) (n = 142) to cisplatin-based chemotherapy. Cisplatin 209-218 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 90-95 22102173-9 2012 CONCLUSIONS: Our results suggest that this polymorphism of ERCC1 at codon 118 is associated with patient response to cisplatin-based chemotherapy in treatments of late-stage NSCLC. Cisplatin 117-126 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 59-64 21676483-7 2012 Subgroup analysis revealed that ERCC1 118 C/T or T/T was associated with increased survival in elderly patients (P=0.018), male (P=0.022), squamous carcinoma (P=0.003), smoker (P=0.076) and those treated with non-gemcitabine/cisplatin or carboplatin (non-GP/GC) regimen (P=0.023). Cisplatin 225-234 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 32-37 22199271-1 2011 BACKGROUND: Overexpression of excision repair cross complementing group 1 (ERCC1), a DNA repair enzyme, is associated with resistance to cisplatin. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 30-73 22199271-1 2011 BACKGROUND: Overexpression of excision repair cross complementing group 1 (ERCC1), a DNA repair enzyme, is associated with resistance to cisplatin. Cisplatin 137-146 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 75-80 21720251-2 2011 Herein we evaluated ERCC1 protein expression in uterine cervical adenocarcinoma and the relationship between this expression, clinicopathological factors, and clinical outcome, particularly in patients receiving adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin. Cisplatin 221-230 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 21720251-2 2011 Herein we evaluated ERCC1 protein expression in uterine cervical adenocarcinoma and the relationship between this expression, clinicopathological factors, and clinical outcome, particularly in patients receiving adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin. Cisplatin 276-285 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 20-25 21720251-8 2011 Among the 25 patients who received cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, those with high ERCC1 expression (n = 5) also experienced significantly worse disease-free survival than those with low ERCC1 expression (n = 20; P = 0.002). Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 117-122 21720251-8 2011 Among the 25 patients who received cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, those with high ERCC1 expression (n = 5) also experienced significantly worse disease-free survival than those with low ERCC1 expression (n = 20; P = 0.002). Cisplatin 35-44 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 221-226 21720251-8 2011 Among the 25 patients who received cisplatin-based chemotherapy or chemoradiotherapy with cisplatin, those with high ERCC1 expression (n = 5) also experienced significantly worse disease-free survival than those with low ERCC1 expression (n = 20; P = 0.002). Cisplatin 90-99 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 117-122 21720251-9 2011 Moreover, univariate and multivariate analyses revealed that high ERCC1 expression was an independent prognostic factor in patients receiving cisplatin-based chemotherapy or chemoradiotherapy with cisplatin. Cisplatin 142-151 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 21720251-9 2011 Moreover, univariate and multivariate analyses revealed that high ERCC1 expression was an independent prognostic factor in patients receiving cisplatin-based chemotherapy or chemoradiotherapy with cisplatin. Cisplatin 197-206 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 66-71 21720251-11 2011 High ERCC1 protein expression was revealed to be associated with worse disease-free survival in the patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin and was shown to be an independent prognostic factor. Cisplatin 131-140 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 5-10 21720251-11 2011 High ERCC1 protein expression was revealed to be associated with worse disease-free survival in the patients who received adjuvant cisplatin-based chemotherapy or chemoradiotherapy with cisplatin and was shown to be an independent prognostic factor. Cisplatin 186-195 ERCC excision repair 1, endonuclease non-catalytic subunit Homo sapiens 5-10